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1. INTRODUCTION 
The incidence of type 1 diabetes (T1D) is increasing by 3–4% annually in most 
countries all over the world (Patterson et al., 2009). The background of such an 
increase is largely unknown (Knip et al., 2005; Onkamo et al., 1999). It is 
widely accepted, that the aetiology of T1D is multifactorial, where the genetic 
disease susceptibility and environmental triggers both play an important role. 
The class II human leukocyte antigen (HLA class II) genes contribute to about 
50% of the overall genetic risk for T1D (Noble et al., 1996; Concannon et al., 
2005). However, in a scenario, where about 20% of Caucasians carry those T1D 
risk conferring HLA genotypes, only 5–10% of such individuals develop clini-
cal T1D (Knip et al., 2005). Even in the geographically close area around the 
Baltic Sea, the incidence of T1D varies between five populations 2 to 6-fold 
(Tuomilehto J et al., 1992; Teeäär et al., 2010; Harjutsalo et al, 2013). Those 
observations support the view that the reasons for the fast and continuous in-
crease in incidence rate must be due to environmental changes (Knip et al., 
2005; Onkamo et al., 1999).  
In many studies, an increased linear growth both in height and weight 
(Bloom et al., 1992; Larsson et al., 2008; Ljungkrantz et al., 2008;) and in-
creased BMI (EURODIAB Substudy 2 Study Group, 2002; Hyppönen et al., 
2000; Knerr et al., 2005) have been observed in children who later presented 
with T1D. Those observations led to the acceleration hypothesis postulated by 
Wilkin in 2001. The hypothesis states that in conditions of food overload, obe-
sity, and accelerated early childhood growth, which are common features in 
modern societies, the demand of insulin production increases, and the overac-
tive β-cells become more susceptible to stress, leading to their apoptosis and 
destruction (Wilkin, 2001). According to the accelerator hypothesis, insulin 
resistance plays an important role, to which excessive weight gain undoubtedly 
contributes substantially (Wilkin, 2008). Insulin resistance promotes metabolic 
upregulation of β-cells with the resulting increase in vulnerability (Wilkin, 
2001) to stress and increased antigenity. The latter could also lead to the in-
creased susceptibility to the autoimmune destruction of islets (Gale, 2005), 
accelerating β-cell loss (Wilkin, 2009). In 2006 Dahlquist expanded the 
accelerator hypothesis to the overload hypothesis stating that any stress will 
make the β-cell more vulnerable to cell damage and initiation of autoimmunity. 
Moreover an almost linear correlation has been shown between increasing birth 
weight (BW) and the subsequent risk for T1D (Cardwell et al., 2010; Harder et 
al, 2009), indicating that accelerated growth as well as other environmental 
determinants of T1D could be important already in intrauterine life.  
The role of genetic factors conferring susceptibility to T1D in the association 
between T1D and increased pre- and postnatal growth is unclear. There are a 
relatively limited number of studies, in which a possible association between 
HLA genotypes conferring risk for T1D and growth has been analysed. In 
previous studies it was found, that some HLA genotypes contribute positively 
and some others negatively to various growth parameters (Carlsson et al., 2012; 
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Larsson et al., 2005; Larsson et al., 2008; Stene et al., 2001; Järvinen et al., 
2008; Yang et al., 2014). Several studies have clearly indicated, that 
environmental factors may modify HLA-related growth (Taylor et al., 2006; 
Hummel et al., 2007; Larsson et al., 2007) Since environmental factors also 
represent the main reasons for the increase in T1D incidence (Knip et al., 2005; 
Onkamo et al., 1999), the potential impact of the HLA genotypes on growth 
could be expected to be strongest in the countries with the highest incidence of 
T1D and accordingly the highest diabetogenic environmental pressure. How-
ever, so far studies have been performed only in countries with relatively simi-
lar incidence rates of T1D and probably a relatively similar environment (Yang 
et al., 2014; Sterner et al., 2011). Accordingly the potential role of HLA geno-
types conferring risk for T1D in pre- and/or postnatal growth remains open.  
As the growth hormone (GH) – insulin-like growth factor I (IGF-I) axis is 
the major determinant of childhood growth, accelerated growth in children who 
later progress to T1D implies a possible role of IGF-I in the pathogenesis of 
T1D. This suggestion is supported by the large body of evidence indicating a 
role for the IGF-I (Agudo et al., 2008; Anguela et al., 2013; Castrillo et al., 
2000; George et al., 2002) and its major binding protein – IGFBP-3 (Jones and 
Clemmons, 1995; Butler et al., 1996; Chan et al., 2005; Kim et al., 2007) in the 
development of T1D. Different animal models have shown, that IGF-I stimu-
lates the replication and proliferation of pre-existing β-cells after damage 
(Agudo et al., 2008), protects β-cells from apoptosis (Castrillo et al., 2000), 
protects islets from lymphocytic infiltration (George et al., 2002), and sup-
presses the progression of autoimmune diabetes (Anguela  et al., 2013). IGFBP-
3 has also IGF-I independent functions (Kim, 2014; Johnson and Firth 2014), 
their role in the pathogenesis of diabetes is not clear, but some studies have 
observed a positive association between circulating IGFBP-3 concentrations 
and type 2 diabetes (T2D) (Frystyk et al., 1999; Rajpathak et al., 2012). There is 
only one earlier study on circulating IGF-I and IGFBP-3 concentrations in 
prediabetic children with early signs of β-cell autoimmunity (Beyerlein et al., 
2014). That study did not find any difference in the serum concentrations of 
IGF-I or IGFBP-3 between subjects developing autoantibodies and autoanti-
body-negative control children (Beyerlein et al., 2014). The possible combined 
impact of the IGF-I/IGFBP-3 system and HLA genotypes on postnatal growth 
has not been studied before.  
The aim of the current study was to analyse the association between HLA 
genotypes conferring risk for T1D and pre- and postnatal growth. Another aim 
was to search for possible differences in the strength of these associations 
among populations with contrasting incidence of T1D. Further the possible 
impact of the IGF-I/IGFBP-3 system on the development of β-cell autoimmun-
ity, and the potential role of the IGF-I/IGFBP-3 system in the HLA- modifying 
effect on postnatal growth were studied. 
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2. REVIEW OF THE LITERATURE 
2.1. Definition and autoimmune  
mechanisms of type 1 diabetes 
Diabetes mellitus is a group of disorders characterized by chronic hyperglycae-
mia resulting from defects in insulin secretion and/or insulin action. Most cases 
of diabetes can be classified into two major subtypes: T1D, characterized by an 
almost absolute deficiency of insulin secretion; or type 2 diabetes (T2D), which 
results from a combination of resistance to insulin and relative insulin defi-
ciency due to inadequate compensatory insulin secretion by the pancreatic β-
cells. T1D represents only about 5–10% of subjects with diabetes, but in many 
populations, especially of Caucasian origin, T1D is the most common form of 
diabetes in young people (Craig et al., 2014). 
T1D is characterized by chronic immune-mediated destruction of the β-cells 
in the pancreatic islets, leading to partial, or in most cases, absolute insulin 
deficiency. The first detectable sign of emerging β-cell autoimmunity is the 
appearance of diabetes-associated autoantibodies (Knip et al., 2005). Several 
studies have shown that autoantibodies often emerge already in very early life 
(Kimpimäki et al., 2001). There are five disease-related autoantibodies includ-
ing islet cell antibodies (ICA), insulin autoantibodies (IAA), autoantibodies to 
the 65 kD isoform of glutamic acid decarboxylase (GADA), the protein tyrosine 
phosphatase-related IA-2 molecule (IA–2A), and zinc transporter 8 autoantibod-
ies (ZnT8A) (Watkins et al., 2014). Some or all of those autoantibodies are 
presented in 85–90% of patients with newly diagnosed T1D (Watkins et al., 
2014). The appearance and the number of those autoantibodies directly predict 
the risk of progression of the β-cell autoimmunity to clinical T1D (Knip, 2002). 
About 70% of subjects testing positive for multiple (≥2) autoantibodies pro-
gressed to T1D over the subsequent 10 years whereas only 15% progressed 
among subjects with a single islet autoantibody (Ziegler et al., 2013).  
It is generally accepted that the destruction of β-cells is mediated primarily 
by cellular immune responses, namely by CD8-positive T cells (Knip and 
Siljander, 2008). This is supported by many arguments. Most important of them 
are the facts that CD8-positive T cells are the major cell types present in insu-
litis, disease progression is delayed by immunosuppressive drugs directed 
specifically against T cells, circulating autoreactive T cells are detectible in 
patients at clinical presentation of T1D (Roep, 2003), and most of the autoanti-
body-negative subjects diagnosed before the age of 40 years have antigen-spe-
cific T-cell response to T1D-related autoantigenes (Lohmann et al., 1997). It 
still remains open whether there is a true autoantibody-negative non-autoim-
mune form of T1D. It is possible, that antibodies are detectable in the preclini-
cal period but turn negative before diagnosis, or the assays are not sensitive 
enough to detect low antibody levels (Sabbah et al., 2000). 
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2.2. Epidemiology, genetic and environmental  
triggers of type 1 diabetes 
2.2.1. Epidemiology of type 1 diabetes 
Convincing data show that the incidence of T1D has started to increase after the 
middle of the 20th century all over the world (Gale, 2002) by 3–4% annually in 
most of the industrialised countries (DIAMOND Project Group, 2006; Onkamo 
et al., 1999). In Finland, where the incidence now is the highest in the world, 
the first nationwide incidence estimation in 1953 showed a rate of 
13/100,000/year, and since then the rate has almost steadily increased by 2.8 
%/year reaching 65/100,000/year in 2006 (Harjutsalo et al., 2013). The increase 
in rates differs significantly between age groups and regions of the world. For 
example, among European countries where the epidemiological data are most 
accurate, the rates of the increase were highest in Central and Eastern European 
countries. Evidence also clearly shows that the increases in incidence rate dur-
ing the last decades of the previous century were highest in the youngest age 
group (EURODIAB ACE Study Group, 2000; Patterson et al., 2009).  
Now the overall standardized incidence of T1D in the world varies 600-fold 
from 0.1/100 000 per year in some regions of China to more than 60/100 000 
per year in Finland (DIAMOND Project Group, 2006; Harjutsalo et al., 2013). 
Interestingly, a remarkable variation in the incidence was found even among 
five populations of a relatively small area around the Baltic Sea (Tuomilehto J 
et al., 1992), where there is now approximately a 2 to 6-fold difference (Teeäär 
et al., 2010; Harjutsalo et al, 2013; Kondrashova et al., 2005). The reasons be-
hind the rapid increase in incidence, including the conspicuous difference seen 
even between neighbouring countries, and the shift in disease manifestation into 
the younger age (Larsson et al., 2004) are largely unknown, but environmental 
changes are the most likely explanation (Onkamo et al., 1999). 
 
 
2.2.2. Genetic determinants of type 1 diabetes 
2.2.2.1. HLA class II genes risk alleles 
The most important genes contributing to the disease susceptibility to T1D are 
the variabilities in the human leukocyte antigen (HLA) region that has been 
estimated to explain at least 50% of the genetic influence in T1D (Noble et al., 
1996; Concannon et al., 2005; Pociot et al., 2010). The HLA system is located 
on chromosome 6p21 and contains many genes related to the immune system. 
HLA are divided into three classes, of which class II is the major genetic 
susceptibility determinant for T1D. HLA class II proteins are coded by DP, DQ, 
and DR loci. The proteins consist of an α and a β peptide chain that are com-
bined to form the heterodimeric class II molecules. Their expression is normally 
restricted only to antigen-presenting cells (APC), B cells and activated T cells 
(Kelly et al., 2003). The physiological role of the molecules encoded by HLA 
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class II genes is the fitting of the immune response by presenting processed 
antigens by APC to the immune system (Knip et al., 2002). 
Susceptibility to T1D is associated with two combinations of DQA1 and 
DQB1 alleles, namely: DQA1*0501-DQB1*0201 and DQA1*0301-
DQB1*0302, which encode the HLA-DQ2 and DQ8 molecules, respectively. 
Two DRB1 alleles, DRB1*03 and DRB1*04 (which encode the DR3 and DR4 
molecules, respectively), are also associated with an increased risk of disease. 
DRB1*03 is in linkage disequilibrium with the DQA1*0501-DQB1*0201 allelic 
combination (forming the DR3-DQ2 haplotype) whereas DRB1*04 is in linkage 
disequilibrium with DQA1*0301-DQB1*0302 (forming the DR4-DQ8 haplo-
type) (Kelly et al., 2003; Eringsmark Regnéll and Lernmark, 2013). Up to 90% 
of patients with diabetes carry one or both of these haplotypes, and the highest 
genetic risk of the disease is conferred by the combination of DR3-DQ2 and 
DR4-DQ8 or more precisely DQA1*0501-DQB1*0201-DRB1*0301 and 
DQA1*0301-DQB1*0302-DRB1*04. Since DR3 and DR4 are in linkage 
disequilibrium with DQ2 and DQ8 respectively, the heterozygous combination 
of those haplotypes is commonly designated synonymously as DR3/DR4 or 
DQ2/8 (Kockum et al 1996). Both components of the haplotype are important in 
relation to the risk of T1D. This is well illustrated by the DR4-DQ8 haplotype 
where DQ8 is the major T1D determinant, but the influence on the disease risk 
may be significantly modified by the DRB1 subtype (Kockum et al., 1999). 
Namely, the DRB1*0401, DRB1*0402, and DRB1*0405 subtypes increase the 
risk of diabetes independent of DQ8, whereas DRB1*0403 and DRB1*0406 
confer protection from the disease (She, 1996, Donner et al., 2000; Undlien et 
al., 1997). The protective effect of DRB1*0403 can override the susceptibility 
conferred by DQ8, even in subjects carrying the highest risk DQ2/DQ8 geno-
type (Kelly et al., 2003). Some other protective alleles in combination with the 
risk alleles also neutralize the disease risk (Erlich et al., 2008). On the other 
hand, alleles such as DQ6.4, DQ5.1, DQ4 or DQ6.3, which are neutral regard-
ing the risk for T1D, are overridden by the risk alleles when combined with the 
DQ2 or DQ8 risk alleles.  
 
 
2.2.2.2. Evidence for a direct role of the HLA-DR and  
HLA-DQ molecules in disease pathogenesis 
The exact mechanisms of HLA-conferred susceptibility to or protection from 
T1D are not completely understood. Long ago it was suggested that the risk 
conferring DR and DQ molecules on the surface of APC are more efficient in 
presenting T1D related autoantigenes to the T lymphocyte in comparison with 
other HLA class II molecules. Vise versa, the protective gene products probably 
bind and present diabetogenic autoantigenes less effectively (Knip et al., 2002). 
Some evidence supporting that suggestion came from studies with x-ray crystal-
lography and computer modeling, which have found that the HLA molecules 
associated with susceptibility to T1D probable have similar chemical and 
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geometric properties in their antigen binding site. These characteristics are 
markedly different from those of protective HLA molecules, which are also 
similar to each other (Cucca et al., 2001; Lee et al., 2001). Some very recent 
transgenic mouse modeling (Skowera et al., 2008; Mohan et al., 2011; Naka-
yama et al., 2005), as well as in vitro human studies (Bulek et al., 2012; 
Kronenberg et al., 2012), have shown evidence indirectly supporting the 
suggestion of a better peptide-binding activity of DQ2 and DQ8 and consecu-
tively a more efficient peptide recognition by T lymphocytes.  
There are also some evidence of other potential mechanisms behind HLA-re-
lated susceptibility to T1D. It has been demonstrated, HLA DQ-conferred ge-
netic risk status is significantly associated with CD4+CD25+(high) T-cell 
apoptosis (Glisic et al., 2009). Those cells are regulatory T-cells (Tregs), nor-
mally preventing or delaying onset of T1D in animal models. Therefore in-
creased Treg apoptosis could accelerate T1D by increased T-cell-mediated de-
struction of β-cells. Subjects with high risk HLA DQB1 genotypes showed 
increased CD4+CD25+(high) T-cell apoptosis compared to subjects with low 
risk HLA DQB1 genotypes (Glisic et al., 2009). 
 
 
2.2.2.3. Other genetic determinants of type 1 diabetes 
HLA class I alleles also contribute to the risk of T1D, although considerably 
less than class II (Eringsmark Regnéll and Lernmark, 2013). In addition to 
HLA, more than 50 other genes outside the HLA region have been found to be 
associated with the increased risk for T1D (Concannon et al., 2009). These 
include the insulin gene, CTLA4, PTPN22, interleukin 2 receptor α (IL2RA), the 
interferon induced with helicase C domain 1 (IFIH1), the CAPSL-IL7R block, 
the lectin CLEC16A, the Th1 transcription factor STAT4, the tyrosine 
phosphatase PTPN2, as well as other loci (Stankov et al., 2013). Their 
individual effects are substantially smaller compared with HLA- DQ and DR. 
Nevertheless, they contribute either to the risk of islet autoimmunity or to the 
progression to clinical T1D in subjects who have developed islet autoimmunity 
(Eringsmark Regnéll and Lernmark, 2013; Pociot et al., 2010; Todd et al., 
2007). 
 
 
2.2.2.4. Prevalence of HLA class II risk alleles in  
the population and environmental pressure 
About 20% of Caucasians carry HLA-conferred susceptibility to T1D, whereas 
the lifetime cumulative incidence of T1D is about 1–2%, indicating that only 
approximately 5–10% of individuals with HLA-determined risk develop clinical 
T1D. This clearly indicates that additional factors are needed to trigger β-cell 
autoimmunity and destruction. The more than 10-fold difference in the inci-
dence of T1D between different Caucasian populations with similar genetic 
background can hardly be explained only by genetic factors (Knip et al., 2005). 
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The significant increase in T1D incidence rate, which started from the middle of 
the 20th century (Gale, 2002), can neither be explained by increased genetic 
disease susceptibility in the population, but must be due to the changes in life-
style and environment (Knip et al., 2005). Moreover, accumulating evidence 
suggests that the proportion of subjects with high-risk conferring HLA geno-
types has decreased over the last decades among patients with newly diagnosed 
T1D, whereas the proportion of people with low-risk or protective HLA geno-
types has increased (Hermann et al., 2003; Gillespie et al., 2004). Available data 
also indicate that the incidence of T1D has increased in population groups who 
have moved from a low-incidence region to a high-incidence area (Åkerblom 
and Knip, 1998). All those data emphasize the role of environmental factors, 
resulting in the progression to clinical diabetes in genetically susceptible, as 
well as in non-susceptible subjects. 
 
 
2.2.3. Environmental triggers of type 1 diabetes 
2.2.3.1. Role of the viruses and bacteria 
At present, there is no obvious environmental candidate trigger of β-cell and 
islet autoimmunity (Eringsmark Regnéll and Lernmark, 2013). Analytical 
epidemiological studies have identified several environmental risk factors, in-
cluding older maternal age, preeclampsia, delivery by cesarean section, in-
creased birth weight, early introduction of cow’s milk proteins, enteroviral 
infections, accelerated postnatal growth and weight gain. (Soltesz et al., 2007). 
As direct triggers of β-cell autoimmunity, multiple factors have been proposed 
starting from viral and bacterial agents, different food components, and a 
combination of food components and microbial agents (Yoon, 1990; Knip et al., 
2005). Observational studies suggest that β-cell autoimmunity may be initiated 
at any age, although a majority of the processes seems to start very early in 
childhood (Leslie and Delli Castelli, 2004). 
Because of very clear seasonal variation in the appearance of the first diabe-
tes-associated autoantibodies and seasonal variation in the presentation of clini-
cal T1D, reported in many Northern Hemisphere studies (Kimpimäki et al, 
2001; Laron Z, 1999; Lévy-Marchal et al., 1995) and in some Southern Hemi-
sphere studies as well (Glatthaar et al., 1988), viruses have been for long 
considered as main candidates for the principle environmental factor initiating 
β-cell autoimmunity (Eringsmark Regnéll and Lernmark, 2013). The peak inci-
dence of T1D is in the fall-winter period and is more pronounced in countries 
with marked differences between summer and winter temperatures (Dahlquist 
and Mustonen, 1994). The role of viruses is also supported, for example, by 
observations of a strong temporal relationship between enterovirus infections 
and the appearance of the first diabetes-associated autoantibodies that was seen 
in several Finnish prospective studies (Hiltunen et al., 1997; Lönnrot et al., 
2000; Lönnrot et al., 2000; Salminen et al., 2003), but not in prospective studies 
coming from other countries (Fuchtenbusch et al., 2001; Graves et al., 2003). 
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However, it should be taken into account that studies where the association 
between β-cell autoimmunity and enterovirus infections was not found, had 
relatively limited number of subjects with positive autoantibodies and wide 
intervals of sampling for enteroviruses. Experimental work has provided evi-
dence that enteroviruses can infect the thymus and alter thymic selection pro-
cesses. Thus, maternal or early life infections may facilitate impairment of cen-
tral tolerance leading to islet autoimmunity (Jaidane et al., 2012). Many studies 
have searched for viruses from the pancreatic tissue. It has been shown that 
enterovirus infection in subjects with persistent islet autoantibodies accelerates 
disease progression from subclinical to overt T1D (Stene et al., 2010). Enterovi-
ruses have also proven to be able to cause a direct infection and damage of β-
cells, (Foulis et al., 1987; Dotta et al., 2007), which could accelerate inflamma-
tion and functional changes in β-cells (Willcox et al., 2011; In’t Veld, 2011). 
The presence of a viral antigen was observed ten times more often in patients 
with T1D compared with controls (Richardson et al., 2009). However, it still 
remains open whether enteroviruses are true triggers or only accelerators of islet 
autoimmunity (Coppieters and von Herrath, 2011). 
The intestinal microbiome represents a complex symbiotic community that 
influences human health, including the teaching and maintenance of the im-
mune system (Wen et al., 2008; Koenig et al., 2011; Arpaia et al., 2013).  Some 
recent studies suggest that gut microbiota may affect the development of islet 
autoimmunity.  For example, the development of diabetes in non-obese diabetic 
(NOD) mice may be influenced by the microbial environment, or by exposure 
to some specific microbial stimuli (Okada et al., 2010). In some rat and NOD 
mouse studies, the decrease of disease risk was shown after antibiotic treatment 
(Wen et al., 2008; Schwartz et al., 2007). Placing the NOD mice from natural to 
pathogen-free settings increased the diabetes incidence (Bach, 2002) whereas 
the exposure to bacterial antigens and infections decreases the risk for T1D 
(King et al., 2011) suggesting that some microbial exposures may protect 
against T1D.  Regarding human studies, one small Finnish cohort study demon-
strated a higher level of Bacteroidetes relative to Firmicutes species approxi-
mately 6 months after birth in those who further developed T1D (Giongo et al., 
2011). A more recent study from Spain showed that children with T1D have 
increased numbers of Clostridium, Bacteroides and Veillonella, and decreased 
numbers of Bifidobacterium and Lactobacillus compared to healthy controls 
(Murri et al., 2013). A detailed study of dynamical changes in gut microbial 
colonisation of infants genetically predisposed to T1D has shown a significant 
decrease in the diversity of gut microbiome in the period between seroconver-
sion and T1D diagnosis accompanied by spikes in inflammation-favoring 
organisms (Kostic et al., 2015). There are also some other studies showing that 
gut micobiota affects the risk of T1D development (Dunne et al., 2014). 
The results of studies investigating the role of viruses and bacteria in the 
development of β-cell autoimmunity are, in general, in line with the so-called 
„hygiene hypothesis“, formulated for the first time by Strachan in 1989 
(Strachan, 1989). This hypothesis proposed that because of modern standards of 
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hygiene and other changes of lifestyle in industrialized countries, the exposure 
to microbes and the infectious burden have decreased. As a result, the develop-
ment of protective immunity throughout childhood is impaired and the suscepti-
bility to allergic diseases is increased. Further, the hypothesis was extended 
from the field of allergy to autoimmune diseases (Bach, 2002). Interestingly, the 
so-called polio hypothesis narrows the hygiene hypothesis arguing that T1D 
incidence rate increases rapidly in countries like Finland and Sweden where the 
frequency of enterovirus infections has decreased over the last decades (Vikari 
et al., 2000). 
 
 
2.2.3.2. Role of vitamin D and other dietary factors 
As it was mentioned above, initial autoantibodies appear more frequently in the 
fall-winter period and show a similar trend from year to year. Based on these 
observations it could be concluded that the trigger of islet autoimmunity should 
show similar seasonal variation. Therefore, some exogenous factors with a sta-
ble or consistently increasing exposure in early childhood, such as most dietary 
components implicated as potential triggers of β-cell autoimmunity, could be 
excluded. (Knip et al., 2005). However, there is a clear seasonal variation in the 
amount of daylight and sunshine hours that naturally causes seasonal variation 
in vitamin D levels. Those variations are especially pronounced in Northern 
Europe, the region with the highest incidence of T1D in the world (Karvonen et 
al., 2000). Therefore, vitamin D has been implicated as a possible trigger of islet 
autoimmunity. Observational studies to test this hypothesis were summarized in 
a meta-analysis (Zipitis et al., 2008) where a decrease in T1D risk was observed 
in infants supplemented with vitamin D. However, our very recent study 
showed that vitamin D status did not differ between subjects positive and nega-
tive for T1D-related autoantibodies (Reinert-Hartwall et al., 2014). On the other 
hand, in Finland, were the vitamin D intake increased significantly from year 
2003, a plateau in the T1D incidence rate was observed from year 2006, indicat-
ing a temporal association between those two events (Mäkinen et al., 2014). 
Thus, the possible role of vitamin D in the pathogenesis of T1D remains open. 
Cow’s milk has also been suggested as a trigger of T1D particularly when 
cross-reactivity was found between bovine and human insulin (Virtanen and 
Knip, 2003). Since the age of cow’s milk introduction depends on breastfeeding 
duration, it has been proposed, that breastfeeding could potentially protect 
against β-cell autoimmunity. However, the data from the literature have shown 
results reporting a protective effect of breastfeeding (Malcova et al., 2006) as 
well as no effect (Couper et al., 2001) on the development of β-cell autoimmun-
ity. Studies on the effect of cow’s milk on the risk of T1D development have 
also led to contradictory results showing that cow’s milk either is a risk factor 
for T1D (Verge et al., 1994; Virtanen et al., 1998) or there is no association 
between the risk for T1D and cow’s milk exposure (Norris et al., 1996; Couper 
et al., 2001). A large meta-analysis, setting out to investigate whether there is a 
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reduced risk for T1D in children being exclusively breastfed for shorter or 
longer period, suggested very weak protective associations (Cadwell et al., 
2012). Data were available from 43 studies including 9,874 patients with T1D. 
Overall, there was a reduction in the risk of T1D after exclusive breast-feeding 
for >2 weeks. Unfortunately, a randomized clinical trial aimed at reducing the 
risk of T1D development in genetically at risk infants (the TRIGR study) 
showed that the use of a hydrolyzed formula during the first 6–8 months of life 
did not reduce the cumulative incidence of T1D autoantibodies after 7 years 
when compared with a conventional formula, (Knip et al., 2014). The trial is, 
however, still continuing to assess whether the early dietary intervention has 
any effect on the development of clinical T1D by the age of 10 years. 
 
 
2.2.3.3. Role of perinatal factors 
Multiple studies have reported different perinatal events as risk factors for T1D. 
Those factors include preeclampsia, high maternal age, birth order, delivery by 
caesarean section, gestational infections, short duration of breastfeeding, and 
some others (Larsson et al., 2004). The results of those studies, however, again 
are inconclusive. Some studies have shown an increased risk for T1D if the 
mother has had an infection with enteroviruses during pregnancy (Dahlquist et 
al., 1995; Hyöty et al., H, 1995). Similar results were later reported by another 
study (Visalli et al., 2003), but not by all studies (Fuchtenbusch et al., 2001). 
Therefore, it is still open whether enterovirus infection during the pregnancy is 
associated with an increased risk for T1D in the offspring (Viskari et al., 2002). 
Delivery by caesarean section and preeclampsia were also reported to increase 
the risk for T1D (Dahlquist et al., 1999; Jones et al 1998), but was not con-
firmed in other study (Stene et al., 2003) In large meta-analysis, where individ-
ual patient data were used, delivery by caesarean section showed increased risk 
for T1D after adjustment for gestational age, birth weight, maternal age, birth 
order, breast-feeding and maternal diabetes (OR 1.19, CI 1.04–1.36) (Cardwell 
et al., 2008). In a similar meta-analysis investigating the effect of maternal age 
on T1D risk, a 5-year increase in maternal age increased the risk for childhood 
T1D by 5% (95% CI 2–9) (Cardwell et al., 2010). 
The reason for conflicting results is probably the small effect of perinatal 
factors on T1D risk. For most of those factors, the odds ratios were between 0.5 
and 1.5. The mechanisms, by which gestational infections, maternal age and 
other prenatal or neonatal events increase the risk for T1D, are not fully under-
stood (Larsson et al., 2004). So far, the most likely perinatal risk factor associ-
ated with T1D risk is birth weight. Two large meta-analyses showed significant 
correlation between increasing birth weight and the risk for development of 
T1D (Cardwell et al., 2010; Harder et al, 2009). The relationships between birth 
weight and risk for T1D are discussed in details below. 
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2.3. Growth in children developing type 1 diabetes later 
2.3.1. Prenatal growth 
Increased prenatal growth resulting in an increased birth weight has been ob-
served to be associated with subsequent risk for development of T1D in many 
studies (Cardwell et al., 2005; Haynes et al., 2007; Stene et al., 2001) whereas 
in some studies no such an association have been seen (Bock et al., 1994; Mal-
cova et al., 2006; Wadsworth et al., 1997), and even a reduced risk has been 
reported (Wei et al., 2006). The interpretation of those diverse results is difficult 
because many studies did not have enough statistical power and they used many 
different groupings or categorisations of birth weight (Stene et al., 2001; Card-
well et al., 2005; Ievins et al., 2007; McKinney et al., 1999; Sipetic et al., 2005), 
or reported findings only for extreme birth weights (Dahlquist et al., 1999; 
Patterson et al., 1994).  In a series of studies birth weight was just a secondary 
characteristic among many other factors, without exact description of methodol-
ogy (Marshall et al., 2004; Polanska et al., 2007; Sadauskaite-Kuehne et al., 
2004; Tenconi et al., 2007; Visalli et al., 2003). Nevertheless two recent 
comprehensive meta-analyses showed almost linear correlation between 
increasing birth weight and the subsequent risk for development of T1D (Harder 
et al., 2009; Cardwell et al., 2010). The meta-analysis by Harder et al (2009) 
included data from 2,398,150 individuals, 7,491 of whom had T1D. The study 
by Carwdell et al (2010) included 12,807 cases with T1D. Both meta-analyses 
showed similar results. In the latter a consistent, but a small increase in the risk 
of T1D was seen in children who were heavier at birth. Children with a birth 
weight of 3.5–4 kg had an increased risk of diabetes of 6%, and children with a 
birth weight more than 4 kg had an increased risk of 10% compared to children 
weighting 3.0–3.5 kg. This corresponds to a linear increase in diabetes risk of 
3% per 500 g increase in birth weight (OR 1.03 (CI 1.00–1.06). After adjust-
ment for maternal age, gestational age, birth order, breastfeeding, caesarean 
section, and maternal diabetes, the results remained the same (Cardwell et al., 
2010). In a big Swedish study (Dahlquist et al., 1996) with 4,584 patients with 
T1D, not included into those two meta-analyses, higher birth weight was also 
associated with increased risk for T1D.  Most of the other similar studies, but 
with smaller number of patients (less than 1000), have showed a modest, and 
not always statistically significant, positive correlation between birth weight 
and risk for T1D (Podar, et al., 1999; Soltesz et al., 1994; Hathout et al., 2006). 
It is unlikely that birth weight plays a direct causal role in the pathogenesis 
of T1D (Cardwell et al., 2010). However, it is possible, that birth weight may be 
a marker of some unknown exposures that influence risk for T1D, for example 
maternal nutrition or maternal diseases (Gluckman et al., 2008). It has been also 
shown that birth weight may predict an earlier onset of the disease without in-
creasing the risk itself (Betts et al., 2005). As fetal insulin is an important 
growth factor, the children with greater intrauterine growth and consequently 
higher birth weight have more active β-cells, producing more insulin (Cardwell 
et al., 2010). Simultaneously, as reviewed by Brown et al, the β-cells actively 
20 
 
secreting insulin are more prone to destruction by various mechanisms (Brown 
et al., 2008). Thus, the association of an increased birth weight with the risk of 
T1D development fits well with the acceleration hypothesis postulated by Wil-
kin in 2001 (Wilkin, 2001). The possible mechanisms behind the acceleration 
hypothesis are discussed below.  
 
 
2.3.2. Early childhood growth 
The association between increased weight gain and the risk of T1D can be oper-
ating also in childhood (Harder et al., 2009) where an increased linear growth 
(Blom et al., 1992; Larsson et al., 2008; Ljungkrantz et al., 2008; Hyppönen et 
al., 2000), weight or BMI (EURODIAB Substudy 2 Study Group, 2002; 
Hyppönen et al., 2000; Knerr et al., 2005) were observed in children who later 
presented with T1D. However, there are some inconsistency and ambiguity in 
the results of the studies that have analyzed the associations between linear 
growth and the risk of T1D. Some studies have demonstrated a positive associa-
tion between T1D and height only in specific subpopulations (Brown et al., 
1994; Japan and Pittsburgh Childhood Diabetes Research Groups, 1989; Songer 
et al., 1986). Brown et al. found a positive association between increased height 
and T1D only in those who had their T1D diagnosed between the age of 5–10 
years (Brown et al., 1994). Those diagnosed under the age of 5 years were 
shorter, and those diagnosed after the age of 10 years were similar in height 
compared to the controls (Brown et al., 1994). Similar results were described by 
Songer and colleagues (Songer et al., 1986). In a family-based case-control 
study, the association of increased growth with the development of T1D was 
limited only to the first year of life (Kharagjitsingh et al., 2010).  Some other 
authors have demonstrated a positive association only for girls (Pond, 1970), 
while others only for boys (Delsten et al., 1981). There are also surveys where 
no differences in height were observed between patients developing T1D and 
the controls (Draminsky Petersen et al., 1978; Choudhury et al., 2000). One of 
the largest studies that assessed the stature of 451 children with T1D at diagno-
sis and more than 10 000 controls, reported that patients less than 1 year of age 
were shorter by 1 standard deviation (SD) and children who developed T1D 
between the age of 3 years and up to puberty were taller by 0.3 SD than the 
controls, but after adjustment for parental height the latter difference vanished 
(DiLiberti et al., 2002). The meta-analysis of 38 earlier publications (DiLiberti 
et al., 2002) paralleled these observations and showed, that children with T1D 
were taller than their controls, except those who developed the disease during 
their first years of life, the latter tended to be shorter, and those who presented 
with T1D in adolescence were of similar height as the controls (DiLiberti et al, 
2002). In the largest existing report where 9248 subjects with T1D were com-
pared with relevant controls, the mean height SD score (SDS) at the time of 
diagnosis was +0.15 (p<0.0001). The vanishing of this difference from early 
childhood to adulthood was also demonstrated in that study (Knerr et al., 2005).  
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There are two interesting studies where subjects from countries with low 
incidence of T1D were included. One of them, where more than 500 subjects 
with T1D were compared with controls, has demonstrated that only children 
from USA (the country with a relatively high incidence of T1D), and only those 
developing T1D before puberty were taller than the controls, whereas newly 
diagnosed children with T1D in Japan had similar height compared to the non-
diabetic population (Japan and Pittsburgh Childhood Diabetes Research Groups, 
1989). In India, where the incidence of T1D is similar to that in Japan, no 
difference in height was seen between subjects with newly diagnosed T1D and 
controls (Ramachandran et al., 1994). These results indicate that in countries 
with different incidence rate of T1D environmental factors may influence differ-
ently the growth of subjects later developing T1D.  
As well as increased height, increased weight and/or BMI have also been 
found to be associated with enhanced risk for T1D (EURODIAB Substudy 2 
Study Group, 2002; Hyppönen et al., 2000; Knerr et al., 2005). The 
EURODIAB multicentre study with approximately 500 T1D subjects and 1,500 
controls observed that the weight SDS was significantly increased among pa-
tients with T1D from the age of 1 month after birth and achieved the maximum 
difference from the controls at the age of 1 to 2 years (EURODIAB Substudy 2 
Study Group, 2002).  The analysis of growth in 600 patients with T1D and 600 
controls in Finland demonstrated that children developing T1D are consistently 
heavier throughout childhood compared to controls. A 10% increment in rela-
tive weight was associated with a 20–60% increase in the risk of T1D (depend-
ing on age). Obesity after 3 years of age was associated with a more than two-
fold risk of developing T1D (Hyppönen et al., 2000). In the largest study from 
Germany and Austria, 9248 children developing T1D had a significantly higher 
mean BMI than the controls in all age groups (Knerr et al., 2005). In the patient 
cohort as a whole, the weight SDS was +0.33 and BMI SDS +0.34 (p<0.00001) 
compared to the reference population. There was also a clear association be-
tween a higher BMI SDS and a younger age at diabetes manifestation, and the 
children diagnosed with T1D under the age of 5 years presented with higher 
weight and BMI SDS than the older patients. A slightly smaller recent German 
study that included about 1000 children with T1D did not, however, find exces-
sive weight gain in any of the examined age intervals before the presentation of 
T1D. Only high birth weight was significantly correlated with increased risk for 
T1D (Kuchlbauer et al., 2014). A recent study, where individual BMI trajecto-
ries of 1011 infants were followed from birth to the age of 2 years, showed that 
an earlier age of the infant BMI peak was associated with the development of 
islet autoimmunity whereas other early growth parameters such as peak height 
velocity, weight velocity, and BMI itself were not (Beyerlein et al., 2014). 
Thus, based on the above studies, it seems that increased BMI and/or weight 
play some role in the development of T1D, at least at a younger age. Many 
large-cohort studies have demonstrated that the strongest association between 
increased BMI and risk of T1D is in the youngest age group (Knerr et al., 
2005). The studies that did not confirm the overall association, often observed a 
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significant association at least in the youngest age group (EURODIAB 
Substudy 2 Study Group, 2002; Ljungkrantz et al., 2008). It has been also 
shown that weight gain in early life may predict the risk of development of β-
cell autoimmunity in children with first-degree relatives affected by T1D 
(Couper et al., 2009). 
There are also studies where correlations between increasing prevalence of 
obesity (and/or increasing BMI), an increasing incidence of T1D and the age at 
diagnosis have been analyzed. For example, a retrospective analysis from the 
USA showed an inverse correlation between the age at diagnosis of T1D and 
BMI (Evertsen et al., 2009). However, the study by Vehik et al. reported that 
only an increased linear growth, but not increased BMI or weight, accounts for 
the younger age at diagnosis of T1D (Vehik et al., 2009). The absence of any 
correlation between BMI SDS and the age at diagnosis has been observed by 
several other studies as well (O'Connell et al., 2007; Dabelea et al., 2006). A 
metanalysis summarizing the results of many studies has concluded that there is 
overall evidence for an association between childhood obesity or higher BMI, 
and increased risk of subsequent T1D (Verbeeten et al., 2011) 
 
 
2.3.3. The acceleration or overload hypothesis;  
the role of insulin resistance 
An explanation for the mechanism(s) behind the association of T1D with a 
higher birth weight, an increased postnatal linear growth, and an increased BMI 
was introduced by Wilkin in 2001. This is the acceleration hypothesis stating, 
that in conditions of food overload, obesity, and accelerated early childhood 
growth, which are common features in modern societies, the demand of insulin 
production increases, and the overactive β-cells become more susceptible to 
stress, leading to their apoptosis and destruction. This could also result in an 
increased antigenicity of β-cells and an increased vulnerability to autoimmune 
destruction (Dahlquist, 2006; Gale, 2005). The acceleration hypothesis assumes 
that there is only one form of diabetes. Age at onset, incidence, and the particu-
lar clinical picture of diabetes, either type 1 or type 2, are all determined by the 
rate of β-cell destruction. The dominating type of destruction, i.e either mostly 
autoimmune or caused more by the insulin resistance, lead to the consecutive 
increased stress of β-cell and their death. The rate of destruction depends on 
environmental factors and pressure (insulin resistance) and the genetic response 
to that pressure (Wilkin, 2009). 
One of the key issues of the acceleration hypothesis is insulin resistance that 
is postulated to be as important in the pathogenesis of T1D as in T2D. Insulin 
resistance leads to metabolic upregulation of β-cells resulting in stress, apopto-
sis and increased antigenity. Subjects with susceptible genotypes will subse-
quently establish an autoimmune response, further accelerating β-cell loss 
(Wilkin, 2009). Weight gain undoubtedly contributes to the insulin resistance 
(Wilkin, 2008). As it was described in details above (Harder et al., 2009; Card-
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well et al., 2010; EURODIAB Substudy 2 Study Group, 2002; Hyppönen et al., 
2000; Knerr et al., 2005), there is a large body of evidence confirming an in-
crease in linear growth and BMI in children later developing T1D. Furthermore, 
there are some indications that children with higher BMI develop T1D at a 
younger age (Kibirige et al., 2003; Betts et al., 2005; Clarke et al., 2006; 
Evertsen et al., 2009), although all studies were not able to endorse that finding 
(Vehik et al., 2009; O'Connell et al., 2007; Dabelea et al., 2006). Moreover, 
there are several observational studies demonstrating that prediabetic children 
are more insulin-resistant compared to their non-diabetic controls (Fourlanos et 
al., 2004; Xu et al., 2007). Fourlanos and colleagues compared the insulin re-
sistance in autoantibody-positive subjects who progressed to T1D with those 
who did not develop T1D. They concluded that insulin resistance is an 
independent risk factor for progression to overt T1D. Progressors had higher 
insulin resistance relative to their insulin secretion at baseline, higher fasting 
glucose, and fasting insulin. The progressors were characterized by an increased 
relative insulin resistance, i.e. the ratio between insulin resistance assessed 
based on the homeostatic model (HOMA-IR) and the first-phase insulin 
response (FPIR) (Fourlanos et al., 2004). In other study, the HOMA-IR and 
FPIR-to-HOMA-IR ratio were also associated with progression to T1D (Xu P et 
al., 2007). However, a large study where intravenous glucose tolerance tests, 
were performed in more than 200 children with HLA-DQB1-conferred 
susceptibility to T1D and advanced β-cell autoimmunity (characterized by the 
presence of multiple autoantibodies), showed that the role of insulin resistance 
in the progression from β-cell autoimmunity to overt T1D is minor, although 
FPIR was confirmed to be a strong predictior of clinical T1D  (Siljander et al., 
2013). Several other studies showed no association between the insulin 
resistance markers and the risk of progression to T1D (Bingley et al., 2008; 
Winkler et al., 2009). In the work of Gardner et al., the correlation between 
insulin resistance and anthropometrics were poor at 5 years of age, but 
strengthened by the age of 8 years (Gardner et al., 2008). 
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2.4. Role of HLA risk genotypes in pre- and postnatal 
growth in children developing type 1 diabetes 
2.4.1. HLA genotypes and prenatal growth  
Since most patients with T1D have particular HLA DQB1 genotypes, it has 
been proposed that those genotypes could, at least partly, explain the association 
between increased growth and risk of T1D. The first study aimed at assessing 
this idea was performed in 2001 by Stene and colleagues. In that study, the 
association between birth weight and HLA DQ genotypes conferring risk for 
T1D was tested among 969 Norwegian non-diabetic children. The investigators 
observed that in contrast to the initial assumption, the HLA genotypes confer-
ring risk for T1D diabetes were associated with reduced birth weight. The mean 
difference in birth weight between subjects with the protective 
DQB1*0602/DQB1*0602 genotype (n=31) and subjects with high-risk 
heterozygous DQ2/DQ8 genotype (n=46) was 354 g (CI 105–604) (Stene et al., 
2001). The next study came from Finland where the association of HLA DRB1 
alleles with birth weight was analyzed in 1263 children and an association be-
tween birth weight and the HLA DRB1*13 allele was found. Infants positive for 
HLA DRB1*13 (n=319) had higher birth weight than infants negative for this 
allele (n = 944; median 3690 g vs. 3650 g, respectively; p=0.044). There was no 
association between other HLA DRB1 alleles and birth weight. However, only 
such DRB1 alleles, the frequency of which exceeded 3% in the screening 
population were analyzed (Aroviita et al., 2004). Subsequently a large study 
came from Sweden, where the association of T1D risk HLA genotypes with 
birth weight was analyzed in 16,709 children born to healthy mothers.  Birth 
weight was expressed in relative units (Z-scores) adjusted for gestational age 
and divided into quartiles. The distribution between the quartiles in children 
with different HLA genotypes was assessed.  The highest quartile was defined 
as high relative birth weight and the lowest quartile as low relative birth weight. 
Genotypes conferring risk for T1D were observed to be strongly associated with 
relative birth weight.  Children with the high-risk genotypes, defined as those 
carrying HLA DQ2/DQ8, HLA DQ8/0604 and HLA DQ8/X genotypes (X was 
not a DQB1*02, 0301, 0302, 0602, 0603, 0604), had higher relative birth 
weight (28% vs 24% in the rest of the population; OR=1.20 (CI 1.08–1.33), 
p=0.0006).  The HLA DQB1*0603 allele, which is protective against T1D, was 
also associated with high relative birth weight (OR 1.13 (CI 1.02–1.28), 
p=0.025). No other HLA risk genotype was associated with high or low relative 
birth weight (Larsson et al., 2005). Those finding confirmed a previous report 
on an association between DQB1*0603-linked HLA DR13 (Aroviita et al., 
2004) and increased relative birth weight, and partially confirmed the finding by 
Stene et al., where the HLA DQB1*0602 allele, closely related to DQB1*0603 
was shown to be associated with increased birth weight (Stene et al., 2001). 
However, in 2006 Stene et al. published a new report, where they performed a 
population-based case-control study including 471 cases with T1D and 1,369 
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control subjects. In a logistic regression analysis, no risk conferring HLA geno-
type contributing to birth weight was identified (Stene et al., 2006).  In a recent 
Finnish study involving 342 children (Järvinen et al., 2008), only the popula-
tion-specific diabetogenic extended haplotype HLA A2,Cw1,B56,DR4,DQ8 was 
associated with high birth weight (p=0.028) in families with a diabetic off-
spring. Other T1D risk conferring HLA haplotypes showed only nonsignificant 
tendency for a higher birth weight (Järvinen et al., 2008). 
 
 
2.4.2. HLA genotypes and environmental interactions 
Many studies have analysed the impact of different environmental factors on the 
relationships between HLA genotypes and birth weight. The study by Taylor et 
al. showed that the interactions between specific fetal HLA DQA1 and DQB1 
alleles and maternal smoking can influence birth weight, thus clearly 
demonstrating that environment is important and may be even a key determina-
tor of the HLA genotype effects on birth weight. The authors compared the 
mean birth weights of 552 newborn infants in UK typed for HLA DQ whose 
mothers had either smoked or not smoked during pregnancy. Maternal smoking 
resulted in significant birth weight reduction, but furthermore, the combined 
effects of maternal smoking and fetal DQA1*0101 or DQB1*0501 alleles re-
sulted in reduction of about 200 g in mean birth weight. In contrast, 
DQA1*0201 and DQB1*0201 (DQ2) alleles showed a protective effect on 
smoking-associated birth weight reduction (Taylor et al., 2006). 
 Other study, emphasizing the importance of environmental effects on ge-
netic background, investigated whether the HLA DR4 (i.e. the DR4-DQ8 haplo-
type) is associated with increased birth weight in a maternal diabetes environ-
ment, and whether these effects could persist during early childhood. Birth 
weight was obtained and the HLA DR typing was performed in singleton births 
from mothers with T1D (n = 1161), and children whose fathers or siblings have 
T1D (n = 872). In addition, the weights and heights of all those children were 
measured at the age of 2 and 5 years. In children born by mothers with T1D, the 
birth weight percentile was positively and independently related to HLA DR4 
alleles (p < 0.0001), while in children from non-diabetic mothers, the HLA DR4 
was not associated with an increased birth weight. Interestingly, the high birth 
weight, but not HLA DR4, was associated with the increased weight and BMI at 
the age of 2 and 5 years (p < 0.0001) (Hummel et al., 2007). As a continuation 
of the study published in 2005, where 16,709 children were tested for HLA 
alleles conferring risk for T1D (Larsson et al., 2005), Larsson with colleges 
studied in a part of those newborn infants whether maternal infections during 
pregnancy have any impact on birth weight. The study showed that the children 
born by mothers reporting fever or gastroenteritis during pregnancy had an 
increased risk of high relative birth weight (p = 0.0003). More importantly, the 
effect of the high-risk HLA DQ2/DQ8 genotype on birth weight was aggravated 
by infections in more than one trimester (OR= 5.24; p = 0.003) indicating again 
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the interaction of HLA DQ-DR alleles with environmental factors, and their 
combined effect on growth (Larsson et al., 2007). Last, but not least, in a study 
investigating 4349 newborn infants typed for HLA alleles conferring risk for 
T1D, a shorter duration of pregnancy was observed in mothers of children with 
high-risk HLA genotypes compared to the low-risk groups  (271.2 ± 11.6 days 
vs. 274.6 ± 12.5 days; p < 0.05) (Locatelli et al., 2007). However, birth weight 
was not observed to be related to HLA risk genotypes, similar to some other 
studies (Aroviita et al., 2004; Stene et al., 2006). 
Since the environment plays an important role in HLA-related differences in 
birth weight, it would be interesting to investigate these associations in coun-
tries with low and high incidence of T1D. To our best knowledge, there has 
been only one study that examined the T1D risk-conferring HLA genotypes 
effect on birth weight in different countries (Sterner et al., 2011). That study 
was performed on the basis of populations from Finland, Germany, Sweden, 
and the United States, i. e. in countries with relatively high T1D incidence 
(DIAMOND Project Group, 2006). The study involved 1495 children and it did 
not reveal differences in birth weight between the HLA risk genotypes.  There 
were some unadjusted differences, but most of them disappeared after adjust-
ment for parental characteristics. Children with the DQ2/DQ2 genotype com-
pared to those with HLA DQ4/DQ8 were heavier only in the US (p=0.028) and 
not in the other counties. This difference, however, was mostly explained by 
parental weight.  Regarding length, the children with DQ2/DQ8 in the US were 
taller compared to DQ4/DQ8-positive infants (p=0.023), but the difference 
disappeared after adjustment for parental height. Only the Swedish children 
with DQ2/DQ8 (p=0.023) and DQ8/DQ8 (p=0.046) genotype were taller inde-
pendent of parental height compared to DQ4/DQ8. There were no other signifi-
cant differences in the anthropometric parameters between newborn infants 
from different countries with various HLA risk genotypes (Sterner et al., 2011).  
 
 
2.4.3. HLA genotypes and postnatal growth 
So far four studies investigating the associations between HLA genotype and 
postnatal growth has been published. The first study, already mentioned above, 
did not find any association between DR4 (or the DR4-DQ8 haplotype) and 
weight or BMI at the age of 2 and 5 years (Hummel et al., 2007). A small co-
hort study from Sweden, where the early postnatal growth data of 58 T1D chil-
dren and 155 controls matched for HLA were analyzed, reported that children 
developing diabetes were significantly taller from 6 to 18 months of age than 
both the non-HLA-matched and the HLA-matched controls, i.e the postnatal 
growth was independent of the HLA genotypes (Larsson et al., 2008). However, 
a recent large study from Sweden (Carlsson et al., 2012), setting out to test the 
hypothesis that the HLA-DQ risk genotypes may be associated with an in-
creased BMI, observed that in overall the HLA DQ risk was inversely associ-
ated with BMI (p < 0.0008). BMI was compared between 2278 children with 
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newly diagnosed T1D and 2000 HLA-matched controls.  Among the patients 
carrying the HLA genotypes associated with the highest risk for T1D 
(DQA1*0501-DQB1*0201/DQA1*X-DQB1*0302 and DQA1*X-DQB1*0302/Z) 
the proportion of overweight or obese subjects was not higher than among the 
controls. Moreover, the proportion of subjects with the highest risk genotype 
decreased along with increasing BMI. Vice versa, the lower risk DQ genotype 
(DQA1*0501-DQB1*0201/ DQA1*0501-DQB1*0201) was associated with an 
increased proportion of patients who were overweight or obese. The odds ratio 
in patients with this genotype of being obese as compared to controls was 1.80 
(CI 1.21–2.61; p<0.006). The highest proportion of overweight patients were 
seen within the group of subjects with the HLA DQA1*0501-DQB1*0201 
haplotype when T1D was diagnosed between 5 and 9 years of age (Carlsson et 
al., 2012). 
The TEDDY Study Group has performed a prospective study comprising 
5969 children with the HLA-conferred susceptibility to T1D from Finland, 
Sweden, Germany and USA, with repeated measurements of weight and height 
between the age of 2 to 4 years. According to their HLA genotypes, the children 
were divided into four groups: those with the DQ2/DQ2, DQ8/DQ8, DQ8/X, or 
DQ2/DQ8 genotypes.  Multivariable logistic regression models were used to 
estimate the risk of being overweight or obese by comparing the proportion of 
those subjects with the HLA genotypes DQ2/DQ2, DQ8/DQ8 and DQ8/X 
against the proportion of obese or overweight subjects with the DQ2/DQ8 geno-
type.  The average BMI was comparable across specific HLA genotypes at 
every age point. The proportion of overweight was not significantly different by 
age, HLA genotypes, or country of residence, but a decreased frequency of 
obesity was observed among those carrying the DQ2/DQ8 genotype 
(p=0.0315). Simultaneously, DQ2/DQ2 was independently associated with a 
significantly higher risk of obesity at age 4 years (n=3252, odds ratio=2.41, CI 
1.21–4.80) (Yang et al., 2014). Both findings are, in general, close to those in 
the study by Carlsson et al (Carlsson et al., 2012).  Last but not least, within 
each country of the TEDDY study, the prevalence of overweight and obesity 
was lower than the country-specific data from similar study cohorts, indicating 
that all children at increased genetic risk for T1D were leaner compared to the 
general population (Yang et al., 2014). A recent study on adults with a slowly 
progressive form of T1D demonstrated that in the lower risk HLA group (all 
T1D risk conferring genotypes excluding HLA DQ2/DQ8 heterozygotes) the 
median BMI of 27.6 kg/m2 was higher compared to 24.7 kg/m2 in the high risk 
HLA group (HLA DQ2/DQ8 heterozygotes) (p=0.03). In the lower HLA risk 
group, 44% of individuals were obese (BMI ≥ 30 kg/m2) compared to 17% in 
the high HLA risk group (p =0.04) (Fourolanos et al., 2014). 
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2.4.4. Conclusions: HLA genotypes and pre- and postnatal growth 
The specific role of HLA genotypes conferring susceptibility to T1D in the 
association between T1D and an increased pre- and postnatal growth is unclear. 
At the moment, there is  a relatively limited number of investigations analyzing 
these associations (Aroviita et al., 2004; Stene et al., Stene et al., 2006; Taylor 
et al., 2006; Larsson et al., 2005; Larsson et al., 2007; Sterner et al., 2011; Hum-
mel et al., 2007; Carlsson et al., 2012; Larsson et al., 2008; Järvinen et al., 2008; 
Yang et al., 2014; Locatelli et al., 2007). Regarding birth weight, only particular 
genotypes or alleles, such as the DQB1*0602/DQB1*0602 genotype (Stene et 
al., 2001), the DQB1*0603-linked HLA DR13 allele (Aroviita et al., 2004), or 
the HLA-DQB1*0603 allele (Larsson et al., 2005), all conferring protection 
against T1D, were shown to be associated with increased birth weight. Other 
studies have demonstrated that most of the HLA genotypes conferring high risk 
for T1D (HLA DQ2/DQ8, DQ8/0604 and DQ8/X) are associated with increased 
birth weight (Larsson et al., 2005; partially in Hummel et al., 2007), whereas 
some other studies have failed to observe such an association (Aroviita et al., 
2004; Stene et al., 2001; Stene et al., 2006; Locatelli et al., 2007; Sterner et al., 
2011).  
Studies on postnatal growth have shown an association between HLA risk 
genotypes and BMI. Two large studies demonstrated very similar results. The 
HLA DQ2/DQ8 genotype linked to the highest T1D risk was associated with a 
decreased BMI, whereas the HLA DQ2/DQ2 genotype linked to a lower risk of 
T1D was associated with increased BMI (Carlsson et al., 2012; Yang et al., 
2014). But there have been also studies where no significant associations were 
seen between HLA genotypes and BMI (Hummel et al., 2007; Larsson et al., 
2008). Recently, Fourlanos with colleagues proposed that the increased BMI in 
adults simply promotes the development of T1D in subjects carrying lower-risk 
HLA risk genotypes by increasing the penetrance of lower risk HLA genes, 
increasing thus the proportion of lower risk HLA genes among subjects with 
higher BMI (Fourolanos et al., 2014). The presence of HLA genotype-related 
differences in BMI in children without any sings of T1D, as reported by Yang et 
al in 2014, speaks against that suggestion. 
Although the specific role of HLA genotypes conferring risk for T1D in pre- 
and postnatal growth remains controversial, it is obvious that HLA genotypes 
may have some distinct impact. The variable and conflicting results may be 
explained by the differences in the incidence of T1D in the background popula-
tion and in the study cohort sizes, but also by different methodologies applied in 
these studies. Moreover, the possible environmental impact on HLA-related 
growth should also be taken into account. As clearly shown in the studies on 
maternal smoking (Taylor et al., 2006), maternal diabetic environment (Hum-
mel et al., 2007), and maternal infections (Larsson et al., 2007), the intrauterine 
environment effects on birth weight are significantly modified by the HLA risk 
genotypes. Many investigators hypothesize that the difference in birth weight 
might be due to the variation in the interactions between the developing fetal 
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immune system and infections defined by differences in HLA genotypes 
(Järvinen et al., 2008; Larsson et al., 2005; Larsson et al., 2007). The same sug-
gestion could be applied on postnatal growth, since various HLA genotypes 
may influence the microbial colonization of the newborn infant, probably due to 
differences in the interactions of microbiota with the immune system (Palma et 
al., 2010; Olivares et al., 2014; Palma et al., 2012; Sánchez et al., 2011).  
As environmental factors have been considered to be the main reason for the 
increase in the incidence of T1D (Knip et al., 2005), the potential impact of the 
HLA genotypes on growth could be defined more closley in studies aimed at 
testing the association between HLA risk genotypes and growth, conducted in 
countries with a contrasting difference in the rate of T1D. However, only two 
such studies have been performed so far, but both in countries with a relatively 
high incidence of T1D (Finland, Sweden, Germany, and USA) (Sterner et al., 
2011; Yang et al., 2014). 
 
 
2.5. Role of the IGF-I/IGFBP-3 system in  
the pathogenesis of type 1 diabetes 
2.5.1. Physiology of the GH-IGF-I/IGBP-3 system 
2.5.1.1. Physiological role of IGF-I  
Growth hormone (GH) is the main regulator of postnatal growth (Ohlsson et al., 
1998). The growth-promoting effect of GH is, to a large extent, mediated 
through stimulation of the expression of insulin-like growth factor I (IGF-I) in 
liver and in other tissues. The liver is the principal source of IGF-I producing up 
to 80% of circulating IGF-I (Sjogren et al., 1999) while the other 20–25% are 
synthesized locally in various tissues (Ohlsson et al., 2000). GH, insulin, and 
the nutritional status are the three main factors regulating the hepatic IGF-I 
biosynthesis, GH being the main regulator (LeRoith et al., 2001). In extrahe-
patic tissues, the IGF-I gene expression is regulated by multiple additional fac-
tors. For example, parathyroid hormone (PTH) (Pfeilschifter et al., 1995) and 
estradiol (Ernst and Rodan, 1991) increase the IGF-I mRNA levels in osteo-
blasts, angiotensin II regulates the IGF-I expression in the cardiovascular sys-
tem (Brink et al., 1999), and thyroid-stimulating hormone (TSH) induces the 
IGF-I expression in thyroid cells (Hofbauer et al., 1995). 
 IGF-I is a multipotent growth factor controlling cell proliferation, 
differentiation, apoptosis, tissue growth and have many organ-specific functions 
(Kooijman, 2006; Frystyk et al., 2010; Dupont and Le Roith, 2001; Kofidis et 
al., 2004) such as bone formation, protein synthesis, glucose uptake in muscle, 
and neuronal survival (LeRoith, 1997). One of the major effects of IGF-I is to 
promote cell survival (Baxter, 2000). The biological functions of IGF-1 are 
mediated through its binding to the type I IGF receptor (IGF-1R), which is a 
transmembrane tyrosine kinase receptor (Siddle et al., 2001; Baserga 2003) 
ubiquitously expressed virtually in all human tissues (LeRoith et al., 1995).  
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2.5.1.2. Physiological role of IGFBP-3 and IGF-I/IGFBP-3 interaction 
The vast majority of circulating IGF-I is bound to a family of six structurally 
and evolutionally related insulin growth factors binding proteins (labeled as 
IGFBP 1–6), more than 95 percent being bound to IGFBP-3 (Jones et al., 1995; 
LeRoith, 1997) which protects IGF-I from destruction prolonging thus its circu-
lating half-life (Butler et al., 1996). More precisely, the majority of IGF-I is 
bound to a large 150-kDa ternary complex that includes IGFBP-3 and the acid-
labile subunit (ALS) (Butler et al., 1996). The circulating concentrations of 
IGFBP-3 are predominantly regulated post-translationally through stabilization 
by its GH-dependent binding partners IGF-I and ALS. Thus, at the serum level, 
IGFBP-3 is GH-dependent (Baxter and Martin 1986), but is GH-independent at 
the transcriptional level (Olivecrona et al., 1999). IGFBP-3 is produced primar-
ily in the liver, and also locally by most tissues (LeRoith, 1997). 
The fact that the circulating IGF-I concentration in adults is approximately 
100 nM and the IGF receptors mostly approach saturation at IGF-I concentra-
tions of 5 nM or lower implies that the regulation of circulating IGF 
bioavailability is a key function of the IGFBPs (Baxter, 2000), probably mostly 
through controlling the access of IGF-I to its receptor (Kim, 2013; Zapf, 1995). 
This role of IGFBP-3 is well illustrated by studies that investigated the actions 
of IGF-I in diabetic nephropathy (LeRoith, 2003). GH and IGF-I were shown to 
affect the diabetic kidney by increasing the renal blood flow and glomerular 
filtration, resulting in an enlarged kidney typical for patients with recent onset 
of diabetes (Flyvbjerg, 2000). In animal studies such kidney enlargement was 
associated with an increased IGF-I concentration in renal tissue, but a signifi-
cant reduction in the overall IGF-I mRNA expression. This resulted in the 
suggestion that IGF-I is trapped in the kidney from the peripheral circulation 
(LeRoith, 2003). Subsequent studies demonstrated that some IGFBPs are ex-
pressed in the kidney more intensively. This led to the understanding that 
IGFBPs play an important role in the presentation of IGF-I to its receptor 
(Landau et al., 1995). Furthermore, a huge complexity of the regulatory actions 
of IGFBPs, including stimulatory, as well as inhibitory effects, on IGF function 
became more evident. The exact mechanisms are still poorly understood, but 
there is some evidence that the binding of IGF-I to its receptors is modulated by 
IGFBP modifications, such as phosphorylation, glycosylation, and proteolysis 
(Baxter, 2000). 
During the past decade a multiple biological functions of IGFBP-3, that are 
considered to be IGF-I independent, became evident (Baxter, 2013; Kim, 2013). 
As first demonstrated in mouse studies, IGFBP-3 inhibits fibroblast growth 
factor (FGF)-stimulated DNA synthesis independently of IGF-I and the effect is 
reversed by IGF-I (Valentinis et al., 1995; Villaudy et al., 1991; Zadeh and 
Binoux, 1997). An independent apoptotic effect of IGFBP-3 was demonstrated 
also in other tissues (Buckbinder et al., 1995; Rechler and Clemmons, 1998, 
Gill et al., 1997). An IGF-independent IGFBP-3 action was observed in the 
IGF-unresponsive breast cancer cell line where IGFBP-3 markedly enhanced 
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the apoptotic effect of the ceramide analog C2 (Gill et al., 1997). Other studies 
revealed that IGFBP-3 is one of the factors preventing cell replication and 
promoting cell death when genomic integrity is compromised (Kinzler and 
Vogelstein, 1997), and contributes to the repair of damaged DNA. At least some 
actions of IGFBP-3 are assumed to be mediated through signaling receptors 
located on the plasma membrane of the target cells (Baxter, 2000) but the direct 
transport of IGFBP-3 to the cell nucleus (Schedlich et al., 1998) and IGFBP-3 
interaction with the retinoid X receptor RXRα, belonging to the family of 
nuclear hormone receptors, have also been demonstrated (Liu et al., 2000). 
 
 
2.5.1.3. Total and free IGF-I 
The measurement of total IGF-I concentration in serum is common clinical 
practice (Shalet et al., 1998; Patel et al., 2000). One of the reasons for using the 
total IGF-I is a lack of reliable assays for the measurement of free IGF-I (Bang 
et al., 2001). However, the judgments cannot rely only on the determination of 
serum total IGF-I, since its level is related to many modulatory factors (Frystyk, 
2004).  For example, in a considerable proportion of patients diagnosed as GH-
deficient, and in some patients with acromegaly, the levels of total IGF-I re-
mains normal (Juul et al., 1997; Peacey and Shalet, 2001; Hoffman et al., 1994). 
Furthermore, in some pathophysiological conditions, such as T1D, obesity, and 
chronic renal failure (Thissen et al., 1994; Feld et al., 1996; Scacchi et al., 1999; 
Bereket et al., 1999) the level of serum total IGF-I is normal, whereas the GH 
level is high, reflecting some degree of disintegration of the GH/IGF-I axis 
caused, in part, by an altered GH sensitivity (Frystyk, 2004).  The interpretation 
of any assay, either for free or for total IGF-I, is also complicated due to the fact 
that IGFBPs are able to alter IGF-I bioavailability and activity even without 
changing the extractable free concentrations of IGF-I (Frystyk, 2004).   
The IGF-I/IGFBP-3 molar ratio is one of the proposed markers of 
bioavailable IGF-I (Juul et al., 1995) and has been widely used in many studies 
(Frystyk, 2004). The usefulness of this ratio, roughly representing the free, also 
called bioavailable, IGF-I, has been demonstrated in many studies (Cortizo et a., 
1998; Smyczynska et al., 2013; Lee et al., 2013, Jung et al., 2014). However, it 
has been actually questioned whether the IGF-I/IGFBP-3 molar ratio is a 
reliable marker of a free bioactive IGF-I as this has not been validated neither 
proven experimentally (Baxter, 2014). In conditions with primary abnormalities 
in GH secretion, the IGF-I/IGFBP-3 ratio changes in the same direction as free 
IGF-I, but with secondary abnormalities in GH secretion, the ratio shows rela-
tively week association with free IGF-I. Therefore, the usefulness of the IGF-
I/IGFBP-3 molar ratio depends on the clinical situation (Frystyk, 2004). 
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2.5.2. Evidence of IGF-I involvement into  
the pathogenesis of type 1 diabetes 
As the GH - IGF-I axis is the major determinant of childhood growth, the 
accelerated growth of children later developing T1D (Cardwell et al., 2010; 
DiLiberti et al., 2002; Knerr et al., 2005; Ljungkrantz et al., 2008) suggests a 
possible role of IGF-I in the pathogenesis of T1D. This assumption is supported 
by the growing number of evidence indicating an important role of IGF-I in the 
regulation of islet β-cell growth, survival and metabolism, mostly providing 
protection against T1D (Smith et al., 1991; Hayakawa et al., 1996; Agudo et al., 
2008; Castrillo et al., 2000; George et al., 2002). 
The ability of pancreas to generate new β-cells in response to an increased 
metabolic demand or after injury has been described in an experimental diabetes 
mouse model (Dor et al., 2004). Moreover, lineage trace analysis provided a 
compelling evidence for β-cell replication as a major pathway for the renewal of 
adult β-cells in mice, both in normal conditions as well as after partial pancre-
atectomy (Dor et al., 2004). Importantly, expansion of β-cell mass after birth 
has also been demonstrated in humans (Meier et al., 2008). The presence of 
IGF-I receptors in islet cells was shown already in 1987 (Van Schravendijk et 
al., 1987). The possible role of IGF-I in the regeneration of β-cells first came 
from studies demonstrating an increased IGF-I expression in the focal areas of 
β-cell regeneration in rats and dogs with partial pancreatectomy (Smith et al., 
1991; Hayakawa et al., 1996; Calvo et al., 1997). IGF-I is able to increase the 
replication and proliferation of β-cells (Agudo et al., 2008; Lingohr et al., 2002) 
and to protect β-cells from apoptosis (Castrillo et al., 2000; Liu et al., 2002). 
Interestingly, in transgenic mouse the liver-specific IGF-I gene deficiency 
caused GH hypersecretion, insulin resistance and accelerated diabetes, whereas 
the pancreatic-specific IGF-I gene deficiency led to a pro-islet environment 
where normal islet growth was stimulated (Lu et al., 2004). However, in a 
mouse model with enriched β-cell-specific IGF-I overexpression, the lack of 
islet hyperplasia was observed in parallel with significant resistance from 
streptozotocin-induced β-cell damage and diabetes (Robertson et al., 2008). The 
inactivation of either the IGF-1 receptor or IGF-I did not alter the development 
of endocrine pancreas in animals (Kido et al., 2002; Kulkarni et al., 2002). 
Those findings led to the concept that IGF-I does not promote β-cell growth or 
replication, but inhibits β-cell apoptosis (Robertson et al., 2008). 
It has also been demonstrated that IGF-I can be directly involved in the 
regulation of immune tolerance. Animal studies showed that the expression of 
IGF-I in the pancreatic islets of transgenic mice protects islets from lympho-
cytic infiltration, reduces cytotoxicity and insulitis induced by low doses of 
streptozotocin (STZ) (George et al., 2002), IGF-I overexpression in the liver 
suppresses the progression of autoimmune diabetes and is associated with a 
decreased islet inflammation (Anguela et al., 2013). In transgenic mice, the 
expression of interferon (IFN)-β in β-cells led to increased islet lymphocytic 
infiltration compared to the controls when treated with low doses of STZ 
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(Casellas et al., 2006). The IGF-I expression in IFN-β–expressing β-cells in 
double-transgenic mice decreased islet infiltration and apoptotic β-cell death 
and in this way protected them from the development of diabetes (Casellas et 
al., 2006). Human in vitro studies showed that the adenoviral gene transfer of 
IGF-I to human islets blocked interleukin-1β (IL-1 β) induced impairment of β-
cell function and apoptosis, and suppressed the recruitment of lymphocytes to 
the islets (Giannoukakis et al., 2000). 
The role of circulating IGF-I in paracrine and autocrine regulation of pancre-
atic endocrine function has not been fully understood.  Nevertheless, it has been 
shown that the systemic administration of recombinant IGF-I to NOD mice 
reduced the severity of insulitis (Mabley et al., 1997; Bergerot et al., 1995; 
Kaino et al., 1996), reduced the T-cell invasion of islets and delayed the onset 
and incidence of diabetes (Bergerot et al., 1995), implying an important role of 
circulating IGF-I in the development of diabetes. There have also been studies 
in NOD mice demonstrating that treatment with IGF-I protects islets against the 
cytokine-mediated inhibition of insulin secretion and cell death by apoptosis 
(Chen et al., 2004).  
 
 
2.5.3. Role of IGF-I/IGFBP-3 in glucose  
homeostasis and insulin resistance 
Increasing evidence indicates that the GH/IGF-I axis plays an important role in 
glucose homeostasis. While insulin is a key short-term regulator of glucose 
homeostasis, IGF-I is involved in the longer term glucose homeostasis, most 
likely by modulating insulin sensitivity (Murphy, 2003). IGF-I has significant 
structural homology with insulin and shares downstream the signaling pathways 
with insulin. Similar to insulin, IGF-I can promote the glucose and fatty acid 
uptake in peripheral tissues (Murphy, 2003; Holt, 2003). A substantial part of 
the non-hepatic circulating IGF-I and IGFBPs originates from adipose tissue 
(Wabitsch et al., 2000). Experimental animal studies and human data demon-
strate that the IGF-I gene mutation results in a state of insulin resistance that 
improves with IGF-I therapy (Yakar et al., 2001; Camacho-Hubner et al., 1999). 
Administration of recombinant IGF-I decreases serum glucose levels and im-
proves insulin sensitivity in healthy individuals as well as in subjects with 
diabetes (Boulware et al., 1994; Moses et al., 1996).  
 It has been hypothesized that the interindividual heterogeneity in endoge-
nous IGF-I and IGFBP levels may influence the risk of developing T2D 
(Rajpathak et al., 2008). Polymorphism in the promoter region of the IGF-I 
gene, present in 12% of Caucasians, was shown to be associated with low IGF-I 
levels and an increased relative risk for T2D (RR 1.7 (CI 1.1–2.7) (Vaessen, et 
al., 2001). Many studies have shown that in obese individuals the total IGF-I 
concentration is normal, whereas free IGF-I is significantly elevated (Frystyk et 
al., 1995; Nam et al., 1997). Unfortunately, there are only few studies 
investigating the association of serum IGF-I level with the risk of developing 
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diabetes. Small-cohort studies have generated contradictory results (Rajpathak 
et al., 2012; Head, et al., 2001; Frystyk et al., 1999). A large cross-sectional 
study in 922 adults older than 65 years, did not find any significant association 
between total IGF-I and increased prevalence of glucose intolerance or diabetes 
(Rajpathak et al., 2008). In a prospective study including 615 subjects aged 45–
65 years a higher IGF-I concentration was associated with a reduced risk of 
developing impaired glucose tolerance or diabetes during follow-up for 4 years 
(Sandhu et al., 2002). In another prospective nested case-control study (742 
subjects matched 1:1 to control subjects) diabetes was not associated with base-
line total IGF-I levels. However, free IGF-I was associated with diabetes. Inter-
estingly, in subjects with high insulin levels, free IGF-I was inversely correlated 
with diabetes development, whereas in subjects with low insulin level, a posi-
tive correlation was seen (Rajpathak et al., 2012). 
As evident from the studies described above, the precise role of IGF-I in 
maintaining normal glucose homeostasis and insulin sensitivity is not well de-
fined. It is, however, clear that IGF-I is necessary for normal insulin sensitivity 
(Clemmons, 2004). Studies have raised the possibility that the relation between 
IGF-I and the risk of diabetes may be bimodal. Among patients with a pre-exist-
ing insulin resistance, the insulin-like activity of IGF-I on glucose uptake may 
attenuate the insulin resistance (Rajpathak et al., 2012). Laboratory studies have 
confirmed this assumption. In parallel with insulin resistance, the insulin/IGF 
hybrid receptor expression is upregulated, thus facilitating the attenuating effect 
of IGF-I on insulin resistance (Federici et al., 1998; Federici et al., 1997). On 
the other hand, prior to the development of insulin resistance, the adverse meta-
bolic effects of IGF-I may predominate. For example, IGF-I accelerated the 
preadipocyte differentiation and proliferation (Boney et al., 1998; Kawai and 
Rosen, 2010). Transgenic mouse models have shown that the reduction of IGF-I 
receptor expression in adipose tissue leads to a reduction in fat mass (Boney et 
al., 1998; Holzenberger et al., 2001). Accordingly, in non-obese subjects the 
IGF-I signaling might promote adiposity and increase the risk of diabetes 
(Rajpathak et al., 2012). 
 
 
2.5.4. IGF-I independent functions of IGFBP-3  
IGFBP-3 has multiple biological functions that are considered to be IGF-I inde-
pendent (Baxter, 2013; Kim, 2013). The possible role of those actions on glu-
cose homeostasis and the pathogenesis of diabetes (either type 1 or type 2) is 
not clear, but many studies imply possible causal associations. First of all, 
IGFBP-3 binds to and co-localizes with retinoid X receptor in the cell nucleus 
(Liu et al., 2000) that is an important transcription factor in glucose homeostasis 
(Rajpathak et al., 2012). Retinoid X receptor is a binding partner for the peroxi-
some proliferator-activated receptor-γ (PPARγ), a nuclear protein that is in-
volved in the transcriptional regulation of enzymes involved in glucose and 
lipid metabolism (Juge-Aubry et al., 1997). Moreover, PPAR-γ plays a role in 
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the regulation of genes that control the differentiation of preadipocytes 
(Morrison and Farmer, 2000) and insulin sensitivity (Lehmann et al., 1995; 
Steppan et al., 2001).  In transgenic mice, the overexpression of IGFBP-3 re-
sults in fasting hyperglycemia, glucose intolerance and insulin resistance (Silha 
et al., 2002). It has also been shown that IGFBP-3 leads to insulin resistance in 
adipocytes (Chan et al., 2005; Kim et al., 2007) and inhibits the differentiation 
of adipocytes (Penkov et al., 2013). In contrast, in a study of IGFBP-3 knock-
out mice the fasting hyperglycemia and hyperinsulinemia suggesting insulin 
resistance were shown (Yamada et al., 2010).  Moreover, a recent study re-
ported that IGFBP-3 can inhibit cytokine-induced insulin resistance in an IGF-
independent manner (Mohanraj et al., 2013).  There are also some human stud-
ies exploring the association of IGFBPs with insulin resistance and diabetes. 
Most of them have shown decreased IGFBP-I level in obese persons, but with 
no significant association between IGFBP-3 and the severity of obesity or 
diabetes (Rajpathak et al., 2008; Sandhu et al., 2002). However, in a small study 
involving 80 subjects, an increased IGFBP-3 level was seen in obese subjects 
compared to lean subjects (Frystyk et al., 1999).  A large prospective case-con-
trol study by Rajpathak with colleagues showed that the baseline serum IGFBP-
3 level was positively associated with diabetes risk (Rajpathak et al., 2012). 
Taking into account the complicated regulatory system of IGFBP-3, it has been 
suggested that in disease state IGFBP-3 may have different functions from those 
seen in healthy subjects (Kim, 2013). As mentioned before, IGF-I is likely to 
have contrasting actions in the pathogenesis of diabetes (Rajpathak et al., 2012). 
The role of the entire IGF-I/IGFBP-3 system in the development of insulin 
resistance and diabetes may be bimodal and strongly depend on the particular 
clinical condition. 
According to the acceleration hypothesis proposed by Wilkin, insulin re-
sistance and obesity play an important role also in the pathogenesis of T1D 
similar to T2D (Wilkin, 2001).  IGF-I and IGBP-3, both involved in glucose 
homeostasis, insulin resistance, β-cell survival, and inhibition of islet autoim-
mune damage (George et al., 2002; Anguela et al., 2013; Casellas et al., 2006; 
Murphy, 2003; Holt, 2003; Robertson et al., 2008), could have an important role 
in the context of the acceleration hypothesis. There are plenty of studies investi-
gating the role of IGF-I/IFBP-3 system in patients with established T1D (re-
viewed by Murphy, 2003; Holt, 2003; Frystyk, 2004; Frystyk, 2014). Despite of 
the large number of studies indicating an important role of the IGF-I/IGFBP-3 
system in the development of T1D (Smith et al., 1991; Hayakawa et al., 1996; 
Anguela et al., 2013; Agudo et al., 2008; Castrillo et al., 2000; George et al.,  
2002), there is only one study on circulating IGF-I and IGFBP-3 concentrations 
in children with early signs of β-cell autoimmunity i.e. in those with diabetes-
associated autoantibodies (Beyerlein et al., 2014). In that study, the differences 
in the serum concentrations of IGF-I and IGFBP-3 at 0, 9, and 24 months meas-
ured in 1011 subject were not associated with the risk of development of β-cell 
autoimmunity. The possible combined impact of the IGF-I/IGFBP-3 system and 
HLA genotypes on growth has never been studied before.  
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3. AIMS OF THE STUDY 
1. To investigate the associations between HLA genotypes conferring risk for 
T1D and birth weight, and search for possible differences in the strength of 
these associations among populations with contrasting incidence of T1D. 
2. To investigate the potential contribution of T1D HLA risk genotypes to the 
observed association between early postnatal growth and risk for T1D in two 
countries with contrasting disease rate. 
3. To investigate the role of IGF-I and IGFBP-3 in the development of β-cell 
autoimmunity (i.e. appearance of autoantibodies) and their potential impact 
on early postnatal growth in children with HLA-conferred susceptibility to 
T1D. 
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4. SUBJECTS AND METHODS 
4.1. Study population 
All study subjects were derived from the international DIABÌMMUNE study, 
aimed at testing the hygiene hypothesis in three neighboring countries with 
conspicuous contrasts in the standard of living and hygiene: Estonia, Finland 
and Russian Karelia. For that purpose the intention was to test between Septem-
ber 2008 and August 2010 about 2500 newborn infants in each country for 
HLA-conferred susceptibility to autoimmunity including T1D and to recruit at 
least 300 predisposed newborn infants for prospective observation up to the age 
of 36 months. The local Ethics committees in all three countries approved the 
study. The parents of the participating subjects gave written informed consent 
for participation in the study, which was carried out in accordance with the 
Principles of the Declaration of Helsinki.  
For the first study data from 8368 newborns tested for HLA DR-DQ alleles 
conferring risk for T1D was used, including 3103 from Espoo, Finland, 2713 
from Tartu and Põlva, Estonia, and 2553 from Petrozavodsk, Karelian Republic 
of Russia. A questionnaire asking about the course of pregnancy, gestational 
age, delivery, child condition at birth, birth weight and length was completed by 
the study nurses during the first 3 days after delivery. At the same time, the 
parents completed a questionnaire on family history. For the subsequent analy-
sis, infants born by mothers with any type of diabetes, from multiple pregnan-
cies, or born before 35 week of gestation were excluded. Late-preterm infants 
(35–36 gestational weeks) were included into the analysis in order to increase 
the statistical power of the study. Overall, the data of 7931 newborns, 2931 
from Finland, 2521 from Estonia and 2479 from Russia were included in the 
analyses. 
For the second study the data of 496 newborn infants with HLA-conferred 
susceptibility to T1D, participating in the follow-up visits at the ages of 3, 6, 12, 
18, and 24 months (± 1 month), was used. In total, there were 235 infants from 
Estonia and 261 from Finland. In addition to those 496 subjects, 191 children 
with a neutral or protective HLA genotype were randomly selected from the 
initial Estonian DIABIMMUNE cohort tested for HLA risk DR-DQ alleles. 
They formed the control group and their linear growth and weight gain data 
were collected from the case records of general practitioners involved in the 
primary care of those children. Data on parental heights were collected for all 
children involved in the study. Children born from multiple pregnancies or 
gestational age of less than 32 weeks were excluded. However, children born by 
mothers with any type of diabetes were included (six mothers with T1D or T2D, 
and 41 mothers with gestational diabetes or impaired glucose tolerance). Such a 
decision was made since in Estonia only risk groups are screened for gestational 
diabetes, which means that up to 50% of the cases remain undiagnosed (Wilcox 
et al., 1996). 
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In the third study subjects were derived from 258 Estonian and 305 Finnish 
children with HLA-conferred susceptibility to T1D as a part of the 
DIABIMMUNE study monitored for the development of diabetes-associated 
autoantibodies from birth up to the age of 36 months. We included all 17 
autoantibody- positive cases from Estonia (four with multiple autoantibodies 
including one case who developed T1D by the age of 2.4 years) and all 23 
autoantibody-positive cases from Finland (eight with multiple antibodies 
including three cases who developed T1D by the age of 2.6, 3.2, and 3.7 years). 
In addition, for every case we selected from the same DIABIMMUNE cohort 
two controls with no diabetes-associated autoantibodies matched for sex, coun-
try of origin, and as close as possible for HLA genotype and date of birth. In 
this way 80 controls were selected for 40 autoantibody-positive subjects. 
 
 
4.2. Methods 
4.2.1. HLA genotyping 
HLA genotyping was performed with a PCR-based lanthanide-labeled 
hybridization method using time-resolved fluorometry for detection as de-
scribed before (Mikk et al.,  2014). The newborn infants were initially analyzed 
for the presence of HLA DQB1*02, DQB1*0301, DQB1*0302 and 
DQB1*0602/3 alleles using a homogeneous screening assay (Kiviniemi et al., 
2007). Depending on the initial result, additional analyses included low resolu-
tion DQB1 full-house typing, DQA1 typing with three allele-specific probes 
and DR4 subtyping (Mikk et al., 2014) Samples positive for the DQA1*05-
DQB1*02 combination (the DR3-DQ2 haplotype) and/or those with 
DQB1*0302/4 without the presence of DRB1*0403/6 (DR4-DQ8) were selected 
as risk-conferring genotypes if no protective haplotype (i.e. DQB1*0602/3, 
DQB1*0503 or the combinations of DQA1*05-DQB1*0301 or DQA1*0201-
DQB1*0303) was present. The original purpose of this screening was to iden-
tify children with increased risk for T1D for follow-up in the DIABIMMUNE 
study. Therefore, if the initial HLA analyses showed definitely protective HLA 
alleles, no further analysis of such alleles was performed. For example, after the 
identification of HLA DQB1*0602/3, further analysis to define whether the 
allele was DQB1*0602 or DQB1*0603 was not performed. Similarly, if the 
original analysis did not find a potential risk genotype no further analyses were 
performed. 
 
 
4.2.2. Assigning study subjects to  
the risk-groups according to HLA genotypes. 
In the first two studies, where also children with neutral and/or protective alleles 
were included, subjects were divided into four groups based on their HLA-
associated risk for T1D. The subjects with the combination of two susceptibility 
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associated haplotypes, i.e. the DR3-DQ2/DR4-DQ8 genotype were categorized 
as the group with very high risk for T1D, those carrying the DR4-DQ8/X geno-
type (X=non-protective allele or haplotype) as a group with high risk and those 
with the DR3-DQ2/X genotype as a group with moderate risk for T1D. All other 
allele combinations were considered as neutral or protective for T1D and sub-
jects, carrying those alleles categorized as the group neutral/protective against 
T1D (Ilonen, 2004) (Table 1). 
In the third study, where children with neutral and/or protective alleles were 
not included all subjects were divided into three groups according to Hekkala et 
al. (Hekkala et al., 2011). The subjects with the DR3-DQ2/DR4-DQ8 genotype 
were categorized as the high-risk group, those carrying the DR4-DQ8/X geno-
type (X= a non-protective allele, but not DR3-DQ2) as a group with moderate 
risk, and those with the DR3-DQ2/Y genotype (Y= a non-protective allele, but 
not DR4-DQ8) as a group with low, though increased, risk for T1D. 
 
 
4.2.3. Assessment of anthropometric parameters 
For the analysis of the association between HLA DR-DQ risk alleles and birth 
weight, relative birth weight was calculated and expressed as a standard devia-
tion score (SDS): SDS=subjects birth weight minus average birth weight [ad-
justed for sex, gestational age (in days) and country of origin] divided by the 
standard deviation (SD) that was calculated for every gestational week, sex and 
country of origin using the study population internal data. 
 
 
Table 1. HLA risk classes for T1D according to their genotype  
Diabetes risk 
HLA DQB1 HLA DRB1 
Haplo 1 Haplo 2 Haplo 1 Haplo 2 
Very high: DR3-DQ2/DR4-
DQ8 *0302/4 *02
a *0401/2/4/5/7/8  
High:  DR4-DQ8/X  *0302/4 X *0401/2/4/5/7/8  
Moderate: DR3-DQ2/X *02a Y   
Neutral or protective  all other all other   
X is not DQB1*02 a,*0503, *0602,*0603, and not a combination of DQB1*0303/DQA1*0201 or 
DQB1*0301/DQA1*05, but homozygosity is possible 
Y is not DQB1*0302,*0503, *0602,*0603, and not a combination of DQB1*0303/DQA1*0201 or 
DQB1*0301/DQA1*05, but homozygosity is possible 
aDQB1*02/DQA1*0501 
 
 
For the analysis of early postnatal growth at each follow-up visit length was 
measured with a length board and weight with a regularly calibrated electronic 
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scale. For all subjects, the data of measurements at the ages of 3, 6, 12, 18, and 
24 months were expressed as standard deviation scores (SDS), calculated based 
on the WHO growth reference data for healthy boys and girls up to the age of 
19 years (WHO Multicentre Growth Reference Study Group, 2006). Since 
every follow-up visit was performed within ± 1 month from the predefined time 
points, the SDS was calculated using the subject’s actual age in days based on 
the corresponding WHO reference data for that age. For each risk-group for 
T1D and each time point the mean length and weight SDS were calculated. 
During the 24-month follow-up period, incomplete data sets of growth (i.e. 
missed at least one growth measurement at some time point) were seen in 12 
subjects in the moderate risk group (6% of all children in that group), in eight 
children in the high-risk group (3%), in one child in the very high risk group 
(2%), and in 51 children in the neutral/control group (27%). As there are no 
WHO reference data to calculate birth weight corrected for gestational age, birth 
weights were expressed only as mean for every risk group. 
 
 
4.2.4. Diabetes-associated autoantibodies 
Insulin autoantibodies (IAA), and antibodies to glutamic acid decarboxylase 
(GADA), insulinoma-associated-2 (IA-2A), and zinc transporter 8 antibody 
(ZnT8A) were analyzed with specific radiobinding assays as described by Knip 
et al. (Knip et al., 2010). The cut-off level was 2.80 relative units (RU) for IAA, 
5.36 RU for GADA, 0.78 RU for IA-2A, and 0.61 RU for ZnT8A. All samples 
obtained from cord blood (0 month) and at the follow-up visits at the age of 3, 
6, 12, 18, 24, and 36 months were analyzed for those four biochemical autoanti-
bodies. Islet cell antibodies (ICA) were analyzed with indirect immunofluores-
cence on human blood group 0 donor pancreas from all samples from any child 
testing positive for one or more of the biochemical autoantibodies. The detec-
tion limit was 2.5 Juvenile Diabetes Foundation units (JDFU). 
 
 
4.2.5. IGF-I and IGFBP-3 measurements 
Plasma concentrations of IGF-I and IGFBP-3 were measured with a solid-
phase, enzyme-labeled chemiluminescent immunometric assay with the 
IMMULITE 2000 analyzer (Diagnostic Products, Los Angeles, CA) according 
to the manufacturer’s protocols. The detection limit for IGF-I was 25 μg/L. 
According to Elmlinger et al. (Elmlinger et al., 2004), the intra-assay and inter-
assay coefficients of variability (CV) for that method are less than 4% and 8%, 
respectively, for IGF-I and less than 4.5% and 7%, respectively, for IGFBP-3. 
In autoantibody-positive subjects, plasma IGF-I and IGFBP-3 concentrations 
were measured from samples obtained at the age when seroconversion to 
positivity for at least one autoantibody was detected (T1), and at the closest 
time-points before (T0) and after seroconversion (T2). For children with multi-
ple autoantibodies, the IGF-I and IFGBP-3 concentrations were measured from 
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all available time points. In controls (autoantibody-negative children) IGF-I and 
IFGBP-3 concentrations were analyzed from samples taken at the same time 
points as in the corresponding case children. The number of subjects studied at 
different time points is presented in Table 2. 
 
 
Table 2. Numbers of IGF-I and IGFBP-3 measurements at various ages in subjects with 
different HLA-related risk for T1D. 
 
 
Age in 
months 
HLA risk-groups  
 
Number of 
subjects with 
seroconversion 
Low risk 
(n=45) 
Moderate risk 
(n=57) 
High risk 
(n=18) 
Aab+ 
(n=15) 
Aab- 
(n=30) 
Aab+ 
(n=19) 
Aab- 
(n=38) 
Aab+ 
(n=6) 
Aab- 
(n=12) 
0 (n=5) 1 3 0 1 0 0 0 
3 (n=19) 3 7 2 6 1 0 1 
6 (n=39) 6 11 5 11 2 4 4 
12 (n=67) 9 16 12 21 3 6 8 
18 (n=98) 12 18 16 34 6 12 12 
24 (n=79) 9 15 15 28 4 8 3 
36 (n=54) 5 7 10 23 3 6 11 
Aab-, Aab+ − Autoantibody negative and Autoantibody positive, respectively. 
 
 
4.2.6. Statistical analysis 
The data were analyzed with the R-program (R 2.15.2, GraphPad, San Diego, 
CA) and SAS (SAS 9.2, SAS Institute Inc., Cary, NC). 
 
 
4.2.6.1. Analysis of the association between birth weight  
and HLA risk alleles for type 1 diabetes 
For the review of general characteristics of the study group, the mean birth 
weight in grams, gestational age, distribution by sex and mean maternal age at 
birth were calculated for all HLA-typed newborn infants in the entire study 
cohort as well as in the individual national cohorts. Comparison between risk-
groups for T1D and between countries were performed using the ANOVA test. 
A p value < 0.05 was considered to indicate a significant difference. 
According to relative birthweights children were divided into quartiles and 
the distribution of various quartiles in each HLA-risk group was compared in 
the whole study group as well as for each country separately. The Chi-square 
test was used for statistical comparison between the groups and quartiles. In 
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order to find factors influencing the birth weight SDS scores, a multiple linear 
regression analysis was also performed. As the country of origin, gender and 
gestational age were already taken into account during SDS calculation, HLA-
risk class (very high, high, moderate, neutral or protective), maternal age and 
route of delivery were included into the multiple linear regression analysis. 
Because all the subjects studied were analyzed for the presence of 
DQB1*02, *0301, *0302 and *0602/3, we also analyzed the distribution of 
subjects between the four birth weight SDS quartiles for all genotypes formed 
by these alleles. 
 
 
4.2.6.2. Analysis of the association between early  
postnatal growth parameters and HLA risk-groups 
Homoscedasticity and homogeneity of mean weight or height SDS of each risk-
group were tested using the Levene’s test. The normality of the length and 
weight SDS distributions in different sub-groups was assessed using the 
Kolmogorov-Smirnov test. At all time points, there was a normal distribution of 
length SDS in all risk groups. The distribution of the weight SDS differed at 
most of the time points from a normal one, but the maximum difference be-
tween group mean and median values did not exceed 0.1 SDS. Therefore, the 
differences in mean length and weight SDSs were compared between the groups 
at different time points using the one-way ANOVA test with post hoc Tukey 
HSD analysis for pair-wise comparison.  
Power calculation, based on the results derived from the entire population 
analysis, was performed for consecutive separate analysis of country-specific 
data. Given the country-specific numbers of study subjects, an effect size of 0.5 
SDS and an SD equal of 1 SDS for mean length and an SD of 0.9 SDS for mean 
weight the power was 42% for length and 86% for weight in the Estonian co-
hort and 29% and 27%, respectively, in the Finnish cohort. 
Since mid-parental height has only a modest effect on linear growth in in-
fancy (Smith et al., 1976), the length SDS data were not corrected for that varia-
ble. However, in order to confirm the absence of any mid-parental height effect, 
this parameter was calculated for each subject using the formula (father’s height 
+ mother’s height+13cm) / 2 for boys and (father’s height + mother’s height –
13cm) / 2 for girls. Subsequently the mean mid-parental height was calculated 
for all risk groups and compared between the groups using the one-way 
ANOVA test. A p value < 0.05 was considered to indicate a significant differ-
ence. 
 
 
4.2.6.3. Analysis of the association between IGF-I/IGFBP-3  
and the development of early signs of β-cell autoimmunity 
The molar ratio of IGF-I/IGFBP3, the possible marker of free bioactive IGF-I in 
plasma (Juul et al., 1995), was calculated on the basis of molecular weights of 
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7.6 kDa for IGF-I (Rinderknecht and Humbel, 1978) and 42 kDa for IGFBP-3 
(Matsumoto et al., 1996) 
The normality of data distribution was assessed based on the Kolmogorov- 
Smirnov test. When the concentration of IGF-I was below the detection limit, a 
level of 25 μg/L was used for the statistical analysis. To compare the possible 
differences in plasma IGF-I and IGFBP-3 concentrations and IGFI/IGFBP-3 
ratios between subjects with different HLA-risk groups for T1D, the ANOVA-
test with post hoc Tukey HSD analysis was used. If the data were not normally 
distributed, the Kruskal-Wallis test with the post hoc Bonferroni (Dunn) t-test 
was applied. For comparison of IGF-I, IGFBP-3, and IGFI/IGFBP-3 molar ratio 
between autoantibody-positive and negative subjects, an unpaired two-tailed 
Student t-test or, in the case of data with a skewed distribution, the Mann-
Whitney U-test were applied. 
The changes in plasma IGF-I and IGFBP-3 concentrations and in IGF-
I/IGFBP-3 ratio were calculated between the time point of seroconverion (T1) 
and the closest time points before seroconversion (T0) to positivity for at least 
one autoantibody (T1 – T0), and also the closest time points after seroconver-
sion (T2 – T1). In matched control subjects the changes in IGF-I and IGFBP-3 
concentrations as well as in the IGF-I/IGFBP-3 ratio were calculated between 
the same time points corresponding to those used in the cases. The paired t-test 
was applied to compare the changes in IGF-I, IGFBP-3 and IGF-I/IGFBP-3 
ratio between cases and controls. 
For the subgroup of autoantibody-positive children with multiple 
autoantibodies (n=12), a paired t-test analysis of possible changes in IGF-I, 
IGFBP-3 and IFG-I/IGFBP-3 ratio between the time points before and at the 
time of seroconversion to positivity for multiple antibodies, was performed as 
well. In addition the four subjects who progressed to clinical T1D were com-
pared to their controls applying the paired t-test. A p value <0.05 was consid-
ered statistically significant. 
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5. RESULTS 
5.1. Birth weights in subjects with  
HLA risk alleles for type 1 diabetes (Paper I) 
5.1.1. General characteristics of the subjects 
The general characteristics of the subjects are presented in Table 3. The mean 
birth weight in Russian Karelia was significantly lower than in Estonia 
(p<0.001) and Finland (p<0.001). The mean age of the mothers at delivery and 
mean duration of pregnancy was also significantly lower in Russian Karelia 
than in Finland and Estonia (both p<0.001). Estonian mothers were younger 
than the Finnish ones, and the duration of pregnancy was shorter in Estonia than 
in Finland (p<0.001). 
 
 
Table 3. General clinical characteristics (mean and 95% CI) of the infants included in 
the study. 
 Finland 
N =2931; 
1402 girls 
Estonia 
N= 2521; 
1231 girls 
Russian Karelia 
N= 2479; 
1191 girls 
Total 
N= 7931; 
3824 girls 
Mean BW (g)
 
 
Girls 
 
Boys 
 
3599  
(3582–3616)* 
 
3542  
(3519–3565) 
3651 
 (3627–3675) 
3627  
(3608–3646)* 
 
3547  
(3521–3573) 
3704  
(3677–3730) 
3452 
 (3434–3469) 
 
3373  
(3349–3397) 
3525  
(3500–3549) 
3562  
(3552–3572) 
 
3491  
(3477–3505) 
3628  
(3613–3643) 
Mean dura-
tion of preg-
nancy (days) 
281.2  
(280.9–281.6)** 
280.2  
(279.8–280.5)** 
277.3  
(277.0–277.6)**
279.7  
(279.5–279.9) 
Mean age  
of mother  
at delivery 
(years)  
31.4  
(31.3–31.6)** 
28.8  
(28.5–29.0)** 
27.6  
(27.4–27.8)** 
29.4  
(29.3–29.5) 
* p<0.001 – compared to Russian Karelia 
**p<0.001 – compared to the other two countries   
 
 
Significant differences in the prevalence of HLA risk genotypes were seen be-
tween the countries, similar to a previous study (Nejentsev et al., 1998). In gen-
eral, very high and high risk genotypes were more prevalent in Finland com-
pared to the other two neighbouring countries. At the same time, the moderate 
risk and neutral or protective genotypes were more frequent in Estonia and 
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Russian Karelia compared to Finland. The detailed description of genotype 
distribution between the study populations is presented in Table 4. 
 
 
5.1.2. The distribution of birth weight SDS between quartiles in 
subjects belonging to different HLA risk groups for type 1 diabetes 
The distribution of newborn infants belonging to various HLA risk genotype 
classes into the lowest and highest quartile of relative birth weight (SDS) is 
shown in Table 5. There were no significant differences between any risk 
groups toward low or high relative birth weight when analyzed either in the 
total study population or separately in the Finnish, Estonian or Russian Karelian 
cohorts. Multiple linear regression analysis showed that maternal age as well as 
delivery by caesarean section were both directly associated with birth weight 
SDS. At the same time, HLArisk class did not significantly influence birth 
weight SDS. Because all the subjects studied were analysed for the presence of 
DQB1*02, *0301, *0302 and *0602/3, we also analyzed the distribution of 
subjects between the four birth weight SDS quartiles for all genotypes formed 
by these alleles. In this analysis, we observed a statistically significant shift 
toward higher relative birth weight for the neutral/protective HLA 
DQB1*0302/DQB1*0602/3 genotype. For this group, the protective alleles 
DQB1*0602 and DQB1*0603 in cross-combination with the risk allele 
DQB1*0302 were associated with increased birth weight. In this group, the 
distribution of children between quartiles was as follows: 18% in the first quar-
tile (the total number, of newborns n=66), 53% in second and third quartiles 
(n=199), and 29% (n=109) in the fourth quartile. The difference between first 
and fourth quartiles was 11% and it was statistically significant [p=0.003; 
OR=0.52 (CI=0.36–0.75)]. Infants with this genotype constitute 4.7% of all 
study subjects and 5.8% of the children with neutral/protective genotypes. The 
distribution of newborn infants with these genotypes over the quartiles was 
similar in all three national groups. The combination of DQB1*0302 or 
DQB1*0602 and *0603 with any other allele did not show significant associa-
tions with increased birth weight (data not shown). 
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Table 4. Distribution of T1D risk-genotypes in the three study populations (Finland, 
Estonia, and Russian Karelia) and differences in their distribution between the countries. 
Diabetes HLA-
risk group Finland Estonia 
Russian 
Karelia  
Very High 2.2%* 1.4% 1.4% 
*Finland vs. Estonia p=0.03  
OR 1.6 (CI 1.5–2.0) 
*Finland vs. Russian Karelia p=0.02   
OR 1.6 (1.1–2.5) 
High 11.7% 4.8%* 8.7%** 
*Finland vs. Estonia p=0.03  
OR 1.6 (CI 1.5–2.0) 
*Finland vs. Russian Karelia p=0.02   
OR 1.6 (1.1–2.5) 
Moderate 9.9% 9.2% 6.8%* 
*Russia Karelia vs. Estonia p=0.002  
OR 1.4 (CI 1.1–1.7) 
*Russian Karelia vs. Finland p<0.001  
OR 1.5 (CI 1.2–1.8) 
Neutral and 
protective 76.2%* 84.6% 83.1% 
*Finland vs. Estonia p<0.001  
OR 1.7 (CI 1.5–2.0) 
*Finland vs. Russian Karelia p<0.001  
OR 1.5 (CI 1.3–1.7) 
 
 
Table 5. The proportional distribution of subjects (%) and numbers (n) in the 1st and 4th 
quartiles of BW SDS in different HLA risk classes for T1D 
HLA-
risk 
group  
Estonia Finland Russian Karelia Total 
Quartile Quartile Quartile Quartile 
 1st 
(<25ts) 
4th 
(>75ts) 
1st 
(<25ts)
4th 
(>75ts)
1st 
(<25ts)
4th 
(>75ts)
1st 
(<25ts) 
4th 
(>75ts) 
Very 
high 
(n=144) 
25% 
(n=10) 
13.9% 
(n=5) 
26% 
(n=17) 
32% 
(n=21) 
29% 
(n=10) 
32% 
(n=11) 
27% 
(n=37) 
 
27% 
(n=37) 
 
High 
(n=675) 
23% 
(n=28) 
23% 
(n=28) 
26% 
(n=90) 
24% 
(n=81) 
22% 
(n=47) 
26% 
(n=56) 
24% 
(n=165) 
24% 
(n=165) 
Moderate 
(n=686) 
23% 
(n=53) 
25% 
(n=58) 
25.9% 
(n=75) 
26% 
(n=76) 
24% 
(n=41) 
28% 
(n=47) 
25% 
(n=169) 
26% 
(n=181) 
Neutral 
and pro-
tective 
(n=6426) 
25% 
(n=540) 
25% 
(n=533) 
25% 
(n=559)
26% 
(n=572)
25% 
(n=513)
24% 
(n=492)
25% 
(n=1612) 
25% 
(n=1597) 
Total 
number   2521 2931 2479 7931 
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5.2. Early postnatal growth in subjects with different  
HLA risk alleles for type 1 diabetes (Paper II) 
5.2.1. General characteristics of the subjects 
The difference in mean BW and mean gestational age between the HLA-related 
risk groups for T1D was non-significant (Table 3). The number and proportion 
of subjects with different HLA risk genotypes in Estonia and Finland are also 
presented in Table 6. The mean duration of breast-feeding varied from 10.0 
months in the moderate risk group to 10.7 months in the very high risk group, 
the difference being non-significant (p=0.16).  
 
 
5.2.2. Comparison of mean length SDS in subjects with  
different HLA risk groups for type 1 diabetes 
The mean length SDS was significantly lower in subjects with very high risk for 
T1D compared to that in subjects in the control group at the age of 12 months 
{0.36 SDS [95% confidence interval (CI) 0.03; 0.70] vs. 0.83 SDS (CI 0.67; 
0.96), p = 0.01} and at the age of 24 months [–0.11 SDS (CI –0.45; 0.20) vs. 
0.47 SDS (CI 0.28; 0.65); p=0.035]. There were no other significant differences 
between the groups (Figure 1). When Estonian and Finnish cohorts were ana-
lyzed separately, a similar pattern in the mean length SDS distribution persisted 
between the groups in both countries (data not shown), but the differences re-
mained non-significant, most likely due to the smaller number of subjects. 
Separate analysis for boys and girls showed that the differences in mean length 
SDS were more significant between the HLA groups among boys (p values 
0.01, 0.08 and 0.002 at the age of 3, 12, and 24 months respectively) whereas in 
girls only non-significant trends could be seen (all p values >0.05). The mean 
mid-parental height was not significantly different between the groups (all p 
values >0.05, data not shown).  
 
 
5.2.3. Comparison of mean weight SDS between subjects  
in different HLA risk groups for T1D 
For the entire study cohort, the weight SDS was significantly lower in subjects 
with the very high-risk genotype for T1D compared to that in subjects in the 
control group at the age of 12 months {0.37 SDS (95% confidence interval (CI) 
0.09; 0.66) vs. 0.92 SDS (CI 0.78; 1.1); p=0.001}, 18 months {0.32 SDS (CI 
0.04; 0.61) vs. 0.89 SDS (CI 0.7; 1.1); p=0.001}, and 24 months {0.34 SDS (CI 
0.06; 0.62) vs. 0.8 SDS (CI 0.59; 1.0); p=0.005} (Figure 2). At the age of 18 
months, the mean weight SDS in the very high-risk group was also lower com-
pared to the moderate-risk group (p=0.03) and the high-risk group (p=0.02) 
(Figure 2). At some time points the mean weight SDS in the control/neutral 
group was also higher than in the moderate and high-risk groups (Figure 2).
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*p<0.05 – very high-risk group versus control group. 
Figure 1. Changes in length SDS in the entire study cohort. 
 
 
 
**p<0.01 – very high risk group vs. control group; #p<0.05– very high risk group vs. moderate 
risk group; ×p< 0.05 – very high risk group vs. high risk group; ‡p<0.05 – control group vs. 
moderate risk group; ‡‡p<0.01 – control group vs. moderate risk group; §§p<0.01 – control group 
vs. high risk group. 
Figure 2. Changes in weight SDS in the entire study group. 
 
 
When analyzed separately, the weight gain among the Estonian children showed 
a similar pattern between the groups as that seen in the entire study cohort: the 
mean weight SDS of the very high-risk group was significantly lower compared 
to the control group at most of the time-points (at 3 months p=0.002; at 12 
months p=0.001; at 18 months p=0.002; and at 24 months p=0.0001), compared 
to the moderate-risk group at 3 months (p=0.04), at 12 months (p=0.04), 18 
months (p=0.03) and compared to the high-risk group at 3, 12, 18, and 24 
months (p=0.01, p=0.01, p=0.006 and p=0.003 respectively) (Figure 3). In addi-
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tion, the mean weight SDS in the control group was higher compared to the 
moderate-risk group at 6 (p=0.01), 12 (p=0.01), 18 (p=0.04) and 24 months 
(p=0.004) (Figure 3). In the Finnish cohort, the differences between the groups 
were not statistically significant. 
Separate analyses for boys and girls showed that the differences in mean 
weight SDS between the groups were significant among the boys whereas in the 
girls no significant differences were seen between the groups (all p values 
>0.05). Namely, in boys the mean weight SDS in the very high-risk group was 
lower compared to the control group at the age of 12 months (p=0.001), and at 
the age of 24 months (p=0.01). In addition, the mean weight SDS in the very 
high-risk group was significantly lower at the age of 12 and 24 months 
compared to the moderate-risk group (p=0.004 and 0.04, respectively), and 
high-risk group (p=0.01 and 0.04, respectively). 
 
 
 
**p<0.01 – very high risk group vs. control group; #p<0.05 – very high risk group vs. moderate 
risk group; ##p<0.01–very high risk group vs. moderate risk group; ×p< 0.05 – very high risk 
group vs. high risk group; ××p< 0.01 – very high risk group vs. high risk group; ‡p<0.05 – control 
group vs. moderate risk group; ‡‡p<0.01 – control group vs. moderate risk group. 
Figure 3. Changes in weight SDS in the Estonian participants. 
 
 
5.3. Role of IGF-I and IGFBP-3 in  HLA risk allele-related 
early postnatal growth and development of early signs of 
β-cell autoimmunity (Paper III) 
5.3.1. Age-associated changes  
in IGF-I, IGFBP-3, and IFG-I/IGFBP-3 ratio in relation to  
HLA risk genotypes for T1D 
In general, there is a rapid decline in IGF-I concentrations after birth up to the 
age of 6 months followed by a gradual recovery until the age of 18 months, 
when the levels are comparable with those at birth. After that the IGF-I 
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concentrations continue to increase slowly. Similar age-related changes were 
also seen in the IGF-I/IGBP-3 ratio. The IGFBP-3 concentrations are in contrast 
lowest in cord blood and increase continuously throughout the study period. At 
the age of 24 months, the mean IGF-I concentration was significantly lower in 
the children carrying the high-risk HLA genotype for T1D in comparison with 
the low-risk group (57.1 μg/L, 95% CI 45.1–69.1 μg/L vs 84.0 μg/L, 95% CI 
68.1–99.8 μg/L, p = 0.02), (Fig. 4). Simultaneously also the mean IGFBP-3 
concentration in the high-risk group (2.3 mg/L, 95% CI 2.1–2.6 mg/L; p < 0.01) 
was significantly lower when compared with both the moderate-risk (2.5 mg/L, 
95% CI 2.4–2.7 mg/L; p < 0.01) and low-risk groups (2.9 mg/L, 95% CI 2.7–
3.2 mg/L), (Fig. 5). There were no differences in the IGF-I/IGFBP-3 ratio at any 
time between the three HLA risk groups (Fig. 6). 
 
 
 
Figure 4. Box plot of plasma IGF-I concentrations over the first 3 years of life in the 
study participants in relation to their HLA risk genotype for type 1 diabetes. The ends of 
the whiskers represent the lower and the upper quartile (Q1 and Q4, respectively). The 
horizontal bar at 0 months represents the value measured for a single subject from the 
moderate-risk group, and that at the age of 3 months is for a single subject from the 
high-risk group. The asterisk marks p = 0.02 for the high risk vs. the low-risk group. 
 
 
5.3.2. Comparison of IGF-I, IGFBP-3, and IFG-I/IGFBP-3 ratio 
between autoantibody-positive and negative subjects 
There were no significant differences in plasma concentrations of IGF-I and 
IGFBP-3 concentrations or IFG-I/IGFBP-3 ratio between the autoantibody-
positive and negative children at any time point from birth up to the age of 36 
months, except a slightly lower mean IGF-I concentration in the autoantibody-
positive subjects (39 μg/L, 95% CI 30–48 μg/L) compared to the autoantibody-
negative infants (48 μg/L, 95% CI 42–54 μg/L) at the age of 12 months (p 
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<0.05), and a slightly lower IGFI/ IGFBP-3 ratio level in autoantibody-positive 
children at the age of 24 months (0.136, 95% CI 0.117– 0.156 vs. 0.151, 95% 
CI 0.140-0.161; p < 0.05). In the four cases who progressed to clinical T1D the 
concentrations of IGF-I and IGFBP-3 as well as the IGF-I/IGFBP-3 ratio were 
not different from other cases or controls. 
 
 
 
Figure 5. Box plot of plasma IGFBP-3 concentrations over the first 3 years of life in the 
study participants in relation to their HLA risk genotype for type 1 diabetes. The ends of 
the whiskers represent the lower and the upper quartile (Q1 and Q4, respectively). The 
horizontal bar at 0 months represents the value measured for a single subject from the 
moderate-risk group, and that at the age of 3 months is for a single subject from the 
high-risk group. The two asterisks mark p < 0.01 for the high risk vs. both the moderate-
risk and low risk groups. 
 
 
 
5.3.3. Changes in IGF-I, IGFBP-3, and IFG-I/IGFBP-3 ratio  
before and after seroconversion 
When comparing the changes in IGF-I and IGFBP-3 concentrations as well as 
in the IFG-I/IGFBP-3 molar ratio between different time points, the mean incre-
ment in IGFBP-3 concentration preceding the seroconverison (T1 – T0) was 
significantly higher in autoantibody-positive children compared to the increase 
during the corresponding time interval in the autoantibody-negative subjects 
(0.43 mg/L 95% CI 0.29–0.56 mg/L vs. 0.22 mg/L, 95% CI 0.1–0.34 mg/L; p = 
0.005; Fig. 7). In addition there was a trend towards a decrease in mean IGF-I 
and IGFBP-3 concentrations after seroconversion among the autoantibody-posi-
tive children (T2 – T1, p = 0.06 for both) compared to the autoantibody nega-
tive subjects. A subcohort analysis of the autoantibody-positive children with 
multiple autoantibodies, and their autoantibody-negative controls did not show 
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any significant differences in the increase in mean IGF-I and IGFBP-3 
concentrations or in the IGF-I/IGFBP-3 molar ratio during the interval before 
and after seroconversion to multiple antibodies. The children who developed 
T1D showed similar trends to the other cases. 
 
 
 
Figure 6. Box plot of plasma IGF-I/IGFBP-3 molar ratio over the first 3 years of life in 
the study participants in relation to their HLA risk genotype. The ends of the whiskers 
represent the lower and the upper quartile (Q1 and Q4, respectively). The horizontal bar 
at 0 months represents the value measured for a single subject from the moderate-risk 
group, and that at the age of 3 months is for a single subject from the high-risk group. 
 
 
 
Figure 7. Mean plasma IGFBP-3 concentrations in autoantibody-positive (Aab+) chil-
dren compared to the controls (Aab-) before (T0), at (T1) and after (T2) seroconversion 
for at least one diabetes-associated autoantibody. The statistical standard error of the 
mean (SE) is shown by error bars. The increase preceding the seroconversion was 
54 
 
significantly greater (** p = 0.005) in the Aab+ children than during the corresponding 
time interval in the Aab- children. 
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6. DISCUSSION 
6.1. Birth weights in subjects with  HLA risk alleles for 
type 1 diabetes (Paper I) 
In our study, we did not find any direct association between HLA-risk geno-
types (DR3-DQ2/DR4-DQ8, DR3-DQ2/X, DR4-DQ8/X) and birth weight. How-
ever, we observed that a relatively high birth weight was associated with the 
protective alleles HLA DQB1*0602 and DQB1*0603, when combined with the 
strong risk allele DQB1*0302. This finding is partially consistent with previous 
studies, where an association of all these alleles with high birth weight has been 
reported (Aroviita et al., 2004; Järvinen et al., 2008; Stene et al., 2001; Larsson 
et al., 2005). The principal difference from previous reports was that in our 
study, only the cross-combinations of these alleles with each other were seen to 
be associated with a significantly increased birth weight, whereas no association 
with increased birth weight was observed if these alleles were combined with 
other alleles. 
 Most previous studies aimed at finding possible associations between HLA 
risk haplotypes for T1D and birth weight have been conducted in one particular 
country. In our study, we set out to investigate whether such an association 
exists in three adjacent countries with similar climate and geophysical condi-
tions but multi-fold differences in the incidence of T1D and conspicuous differ-
ences in socio-economic level and living environment. Because environmental 
factors are most likely the main factors (Onkamo et al., 1999) responsible for 
the increase seen in T1D incidence over the last decades in developed countries 
(DIAMOND Project Group, 2006), we hypothesized that the impact of the HLA 
haplotype on birth weight would be strongest in the country with the highest 
incidence of T1D, that is, in Finland (Harjutsalo et al., 2013). Some observa-
tions speak in favor of this hypothesis. It has for example, been reported that 
some environmental factors such as maternal smoking and intrauterine infec-
tions may influence fetal growth modulated by HLA genotypes (Taylor et al., 
2006; Larsson et al., 2007). Various HLA genotypes may influence for exam-
ple, the microbial colonization of the newborn infant (De Palma et al., 2010). 
Therefore, differences in such factors between the countries studied here could 
potentially influence the association between the HLA genotype and birth 
weight. However, the distribution of birth weight over quartiles in different 
HLA risk classes or their combinations was not significantly different in any of 
the countries studied or in the whole study cohort. Even in groups with a non-
homogeneous distribution of birth weight over quartiles, such as in the case of 
HLA DQB1*0302/DQB*0602/3, no significant differences was seen between 
Finland, Estonia and Russian Karelia.  
One reason why we did not detect any association between common HLA-
risk genotypes and birth weight might be the relatively small number of subjects 
in each country for the detection of such an association as that one seen in the 
Swedish study comprising 16 709 newborn infants (Larsson et al., 2005). The 
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second reason might be slightly different classifications applied for HLA risk 
categories. For example, in our study, DR4 in DQB1*0302 positive subjects 
was additionally subtyped to find the protective allele DRB1*0403 in order to 
exclude those subjects from the high-risk group. However, after applying ex-
actly the same classification for HLA risk groups as that one used by Larsson et 
al. (Larsson et al., 2005), the distribution of children over quartiles remained the 
same as in our initial analysis (data not shown). The third reason might be the 
difference in how birth weight SDS was calculated. In the Swedish study 
(Larsson et al., 2005), the birth weight SDS was based on the mean birth weight 
derived from national standardized intrauterine growth curve. In our study, such 
a standardized curve was available only for the Finnish cohort (Pihkala et al., 
1989). The comparison of Finnish birth weight data (mean birth weight by 
gestational week and sex and their standard deviation) with the Finnish national 
reference growth curve showed that at least this national cohort represented the 
general population very well (data not shown). 
One might also expect an effect opposite to our hypothesis. Namely, in Fin-
land, where the incidence of T1D is the highest, the effect of HLA on birth 
weight may remain unrecognized because of other powerful risk factors affect-
ing birth weight. Under such circumstances, an effect of HLA on birth weight 
could be expected to be seen in countries with lower prevalence of T1D. How-
ever, both in Estonia and Russian Karelia, no such differences in birth weight 
distribution were observed. There have also been other studies looking for 
possible associations between HLA risk group and birth weight (Stene et al., 
2001; Locatelli et al., 2007; Järvinen et al., 2008; Hummel et al., 2007). 
Järvinen with colleges demonstrated in 2008 that only one population-specific 
relatively rare DQB1*0302-DR4 haplotype with the B56 allele conferring in-
creased risk for T1D was associated with higher birth weight, whereas other 
HLA haplotypes conferring risk for T1D were associated with only a modest 
and non-significant trend toward higher birth weight. In a German study (Hum-
mel et al., 2007), the association of HLA DQB1*0302-DR4 with high birth 
weight was demonstrated only in offspring of diabetic mothers. Our results are 
more similar to those reported by Stene et al. and Locatelli et al. who did not 
find any significant associations between a high birth weight and HLA haplo-
types conferring increased risk for T1D. (Stene et al., 2001; Locatelli et al., 
2007) Our results also agree with the outcome of the recent study by Sterner et 
al., where the populations of four countries with similar socioeconomic level 
but with different climatic conditions and genetic background were compared, 
and no difference between groups with different HLA-risk genotypes was seen 
(Sterner et al., 2011). 
We observed a positive association between the HLA genotype and in-
creased birth weight for the HLA DQB1*0302/DQB1*0602/3 combination. 
Stene et al. demonstrated a positive association between high birth weight and 
the protective HLA DQB1*0602 allele. (Stene et al., 2001). Other authors have 
noticed some associations between an increased birth weight and the protective 
HLA DQB1*0603 allele (Larsson et al., 2005) and the predisposing allele HLA 
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DQB1*0302 allele (Larsson et al., 2005; Järvinen et al., 2008; Hummel et al., 
2007). We suggest that these alleles have an additive effect on birth weight and 
when combined, the effect on birth weight is most obvious. If those alleles are 
present separately, the additive effect vanishes and in our study, we did not see 
any impact on birth weight. 
Our study has a couple of limitations. First is the selection bias. Because of 
technical difficulties in emergency situations, the cord blood samples were not 
obtained from a few children born by caesarean section. We were not able to 
find out the exact number of such missed subjects. Therefore, the data of these 
children who are often extremely large or because of their prematurity very 
small are missing in the study. The second limitation is a possible information 
bias. Namely, the gestational age of some infants might be misclassified. One 
sign of such a possible misclassification is the fact that the duration of preg-
nancy was statistically different between the countries. This might be caused by 
the differences in the methodology of estimation of pregnancy duration between 
the countries. In our SDS calculation, however, we have taken into considera-
tion the country of origin and therefore the influence of possible misclassifica-
tion of gestational age should be eliminated. The third limitation is that we were 
not able to identify exactly the number of previous deliveries by the mother. We 
asked about the number of siblings but not about the number of previous 
deliveries. Therefore, we could not adjust the birth weight data for birth order. It 
is known that the birth weight is increasing along with birth order in singleton 
pregnancies (Wilcox et al., 1996). However, many studies on HLA associations 
with birth weight have shown that adjustment for birth order does not influence 
the results (Larsson et al., 2005; Locatelli et al., 2007; Hummel et al., 2007); 
and therefore, we may assume that the same is true for the current study. In 
addition, birth weight is influenced by many biological, medical and socioeco-
nomic factors, information of which was not available and thus could not be 
adjusted for neither in previous studies nor in the current study.  
To conclude, in this study, we were not able to confirm the previously re-
ported observation of an association between common HLA risk haplotypes for 
T1D and increased birth weight. However, we found a significant association 
between increased relative birth weight and two strongly protective alleles in 
cross-combination with the DQB1*0302 risk allele. Further comprehensive 
epidemiological studies are needed to assess to which extent HLA haplotypes 
conferring susceptibility to T1D are contributing to the increased birth weight 
associated with enhanced disease risk and the role of different environmental 
factors in this process. Our observations suggest that the mechanisms behind the 
association between high birth weight and risk for T1D could be related to other 
factors than the HLA genotypes.  
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6.2. The role of HLA risk alleles for type 1 diabetes in 
early postnatal growth (Paper II) 
In this study we showed that the early growth pattern in children carrying high-
risk HLA genotypes for T1D differs significantly from that seen in other young 
children. In particular, up to the age of 24 months the children in the very high-
risk group had gained significantly less weight compared to the children in the 
other groups. The same pattern was also seen in length, but it was less conspicu-
ous. Similarly to the very high-risk group, at some time points children in the 
other risk groups gained less weight than those with neutral genotypes.  
The current results were surprising because the majority of previously pub-
lished studies have reported a positive correlation between increased linear 
growth, weight gain, and development of T1D (Blom et al., 1992; Bognetti et 
al., 1998; Ljungkrantz et al., 2008; Larsson et al., 2008; Hyppönen et al., 2000; 
EURODIAB Substudy 2 Study Group, 2002; Knerr et al., 2005). Therefore, we 
also expected a similar positive correlation between growth and HLA-conferred 
risk for T1D. However, there are also reports, in which inverse association 
(Brown et al., 1994; DiLiberti et al., 2002; Leslie et al., 1991), or positive 
associations only in some specific subgroups (Brown et al., 1994; Japan and 
Pittsburgh Childhood Diabetes Research Groups, 1989; DiLiberti et al., 2002; 
Songer et al., 1986; Leslie et al., 1991; Kharagjitsingh  et al., 2010) have been 
observed between risk for T1D and accelerated growth. The principal difference 
between our study and the previous ones is that we monitored prospectively a 
cohort of children carrying HLA genotypes conferring genetic susceptibility to 
T1D, while earlier studies have analyzed growth data retrospectively in children 
with established T1D. Moreover, the role of HLA genotypes conferring 
susceptibility to T1D is not well defined earlier in relation to linear growth and 
weight gain (Court et al., 1982; Larsson et al., 2008; Carlsson et al., 2012). The 
recent Swedish study by Carlsson et al., which investigated the association be-
tween BMI and HLA genotypes conferring risk for T1D in 2403 children with 
recent-onset T1D, showed that disease development was associated with in-
creased BMI in subjects with low or moderate risk HLA genotypes, i.e. the 
association was positive, whereas in the group with the highest genetic risk, the 
development of T1D was associated with low BMI, i.e. there was an inverse 
association (Carlsson et al., 2012). Very similar results were also recently 
shown in another large study (Yang et al., 2014). Those findings are in line with 
our results.  
The current study confirms that the association between different HLA geno-
types and weight and length gain is directly related to the HLA genotypes. For 
example, an inverse association between linear growth and presentation of T1D 
has been observed in children who developed T1D early in life (Brown et al., 
1994; DiLiberti et al., 2002). It has also been shown that the HLA genotype 
conferring very high risk for T1D (HLA DR3-DQ2/DR4-DQ8) is overrepre-
sented among those who present with overt disease before the age of 5 years 
(Gillespie et al., 2002). Accordingly, when combined, those observations are 
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consistent with the current finding of a retarded growth among children who 
carry the HLA genotype conferring the highest risk for T1D.  
It should be noted that any direct linking of our results with the development 
of T1D should be avoided, since the vast majority of children with HLA-con-
ferred risk for T1D will never develop diabetes (Erlich et al., 2008; Knip et al., 
2005). Information on the progression of the autoimmune process towards clini-
cal T1D would provide additional light on the possible link between the growth 
pattern and the development of T1D, but only a few subjects seroconverted to 
positivity for T1D-associated autoantibodies by the age of 24 months. 
We found some differences in the growth pattern between the two countries 
represented in this study. While the mean length SDS changes in all risk groups 
showed similar patterns in both countries, the weight SDS of the very high and 
moderate-risk groups was significantly lower at several time points over the 
study period compared to the control group only in Estonia, but not in Finland. 
Increased growth and weight gain are known to be risk factors for the develop-
ment of T1D (Blom et al., 1992; Bognetti et al., 1998; Ljungkrantz  et al., 2008; 
EURODIAB Substudy 2 Study Group, 2002; Hyppönen et al., 2000; Kibirige et 
al., 2003; Knerr et al., 2005). Our hypothesis at the beginning of the study was 
that some unknown environmental exposures, associated with the development 
of T1D, also promote a more rapid weight and length gain and this phenomena 
is more obvious in children from Finland, were the incidence of T1D is approxi-
mately three times higher than in Estonia (Teeäär  et al., 2010; Harjutsalo et al., 
2013). This hypothesis is supported by studies showing that in countries with 
low T1D rates (such as India or Japan), no positive correlation has been ob-
served between rapid linear growth and further development of T1D (Japan and 
Pittsburgh Childhood Diabetes Research Groups, 1989; Ramachandran et al., 
1994).  
The differences in growth pattern depending on T1D-related HLA genotypes 
could be explained by the role of insulin resistance which has been shown to 
contribute to the development of T1D in several studies (Fourlanos et al., 2004; 
Gardner et al., 2008; Xu P et al., 2007). Rapid weight gain has been observed to 
be associated with insulin resistance (Mericq et al., 2005). Children with neutral 
and protective HLA genotypes could have a higher degree of insulin resistance 
compared to those with high-risk HLA genotypes. This idea is supported by the 
recent study by Andersen et al. who reported a positive association between 
stronger HLA-conferred susceptibility to T1D and lower insulin secretion, bet-
ter insulin sensitivity, and a reduced capacity to compensate for an increasing 
insulin demand in adults (Andersen  et al., 2012). Unfortunately, we do not have 
any data on insulin resistance in our study subjects, and therefore this explana-
tion is only hypothetical.  
There are several major strengths of our study. It is one of the largest studies 
which has analyzed the association between different T1D risk-related HLA 
genotypes and early growth. Moreover, previous studies have focused mostly 
on the association between growth and further development of T1D. In such 
studies the HLA genotypes have been considered as potential confounders, and 
60 
 
their possible effect on growth has been analyzed accordingly (Court et al., 
1982; Larsson et al., 2008). To our best knowledge, this study is the first one 
directly focusing on the effect of HLA genotypes conferring susceptibility to 
T1D on postnatal growth. Previous studies on the HLA impact on growth have 
been mostly case-control studies. There is only one earlier study, in which sub-
jects with genetic risk for T1D were allocated according to their HLA geno-
types and thereby providing the possibility to assess the potential effect of spe-
cific HLA genotypes on growth characteristics (Carlsson et al., 2012). Gener-
ally speaking, the results of that study were in line with our results. Recently 
our results have been reproduced by another large cohort study (Yang et al., 
2014). Another strength of our study is the inclusion of subjects from two coun-
tries with similar genetic background and close geographic location, but with 
about a threefold difference in the incidence of T1D (Teeäär et al., 2010; 
Harjutsalo et al., 2013), suggesting a possible major impact of the environment 
and lifestyle on the development of the disease. The conspicuous difference in 
the T1D rate between Estonia and Finland must be explained mostly by 
environmental and lifestyle differences between these two countries.  
The major limitations of our study are related to the control/neutral group. 
This group included only children from Estonia whereas the risk groups for 
T1D comprised subjects from both Estonia and Finland. When comparing 
growth charts of Estonian and Finnish children, the mean height and weight at 
the age of 2 years are very similar (88.5 cm/13400 g vs. 88cm/13000g in boys 
and 87.5 cm/12500 g vs. 86.6/12500 in girls, respectively). Accordingly we do 
not expect that the growth pattern in Finnish children with protective or neutral 
HLA genotype would have been significantly different from that seen in Esto-
nian children. Moreover, the mean birth weight of newborn infants carrying 
neutral or protective HLA genotypes, as well as the mean birth weights of 
babies with other HLA genotypes, were not significantly different between 
these two countries (Peet et al., 2012). The second limitation, also related to the 
control group, is the fact that the subjects in this group were followed not within 
the framework of the DIABIMMUNE study but by their primary care physi-
cians. However, the weight and length measurements are well standardized in 
young children, and therefore the growth data collected from the primary care 
case records can be expected to be reliable and comparable with the data col-
lected within the DIABIMMUNE project. The third limitation, also related to 
the control group, was a relatively high proportion of incomplete growth data 
sets within this group as 27% of the subjects had one or more missing data point 
during the study period while this proportion was only 1 to 5% in the risk 
groups. Such a high number of missing data is due to the fact that the 18-month 
visit to a primary care physician is not obligatory in Estonia, and therefore 
many families do not attend.  Another limitation of the current study is the low 
number of children in the very high risk group (n=45). It leads to significant 
lack of power in country-specific analysis and a high likelihood of false-nega-
tive results in comparison of Estonian and Finnish subgroups. In addition, there 
are some possible confounders, such as the children’s diet, frequency of 
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intermittent diseases or medications, that could have an influence on the results, 
but the detailed analysis of their impact was beyond the scope of the current 
study.  
In conclusion, we have observed that early growth was significantly slower 
in children with HLA genotypes conferring very high risk for T1D than in those 
with neutral or protective HLA genotypes. Contradictory to our initial hypothe-
sis, the subjects with very high risk gained less weight and height during the 
first 24 months of life, and this was more pronounced in the Estonian cohort. 
From these observations we hypothesize that the development of T1D requires a 
higher degree of insulin resistance among children with neutral and protective 
HLA genotypes when compared to those with high-risk genotypes, and this 
seems to be the case more so in Estonia with a median disease incidence than in 
Finland with the highest rate of T1D in the world.  
 
 
6.3. The role of IGF-I and IGFBP-3 in HLA risk allele-
related early postnatal growth and development of early 
signs of β-cell autoimmunity (Paper III) 
In this study we observed several significant associations between the IGF-
I/IGFBP-3 system on one hand and the development of diabetes-associated 
autoantibodies and HLA genotypes conferring risk for T1D on the other. First 
of all, we found that at the age of 24 months the mean IGF-I and IGFBP-3 con-
centrations in subjects with the high-risk HLA genotype for T1D (DR3-
DQ2/DR2-DQ8) were significantly lower compared to the subjects with low-
risk HLA genotypes. The results are in line with our previous study in the entire 
DIABIMMUNE study cohort where we found that by the age of 18–24 months 
the subjects with high HLA risk-genotypes for T1D demonstrated a pronounced 
slowdown in linear growth as well as in weight (Peet et al., 2014). The current 
results suggest that the decreased circulating IGF-I and IGFBP-3 concentrations 
may be involved in the slower growth in children carrying the high-risk geno-
type. In the study by Beyerlein et al. the association of IGF-I and IGFBP-3 in 
relation to HLA status was not analyzed (Beyerlein et al., 2014). 
The GH-IGF-I axis starts to play a major role in the regulation of human 
growth from the age of around 2 years (Karlberg, 1989). This may explain why 
the difference in IGF-I and IGFBP-3 concentrations between subjects with 
different HLA genotypes was seen only at the age of 24 months and not before. 
Accordingly, it would be interesting to follow these children to see whether a 
slower growth rate and lower IGF-I and IGFBP-3 concentrations will continue 
to persist or whether this is just a temporary finding followed by some catch-up 
both in growth as well as in hormone concentrations. Studies in slightly older 
children (Yang et al., 2014; Carlsson et al., 2012) and in adults (Fourolanos et 
al., 2014), in whom increased HLA-conferred risk for T1D was observed to be 
associated with lower BMI, indicate that the former scenario is more likely to 
occur. We suggest that the slower linear growth and weight gain in 
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DIABIMMUNE subjects (Peet al., 2014) and lower BMI in other children and 
adults with high HLA-conferred risk for T1D (Yang et al., 2014; Carlsson et al., 
2012; Fourlanos et al., 2014) may be associated with lower circulating 
concentrations of IGF-I and IGFBP-3 concentrations. It is known that IGF-I has 
a protective effect on the process of autoimmune destruction of the β-cells 
(Castrillo et al., 2000; George et al., 2002; Anguela et al., 2013; Chen et al., 
2004; Mabley et al., 1997; Bergerot et al., 1995). Since the mechanisms behind 
the HLA-conferred genetic susceptibility to T1D are poorly defined (Xie et al., 
2014), we could speculate that the reduced IGF-I concentrations in subjects 
with the high-risk HLA genotype could explain, at least partly, the HLA-related 
risk for T1D given that high IGF-I concentrations are protective against the 
development of T1D (Castrillo et al., 2000; George et al., 2002; Anguela et al., 
2013; Chen et al., 2004; Mabley et al., 1997; Bergerot et al., 1995). Fourlanos et 
al. proposed, however, recently that an increased BMI simply promotes the 
development of T1D in subjects carrying lower-risk HLA risk genotypes by 
increasing the penetrance of lower risk HLA genes, increasing thus the propor-
tion of lower risk HLA genes among subjects with higher BMI (Fourlanos et al., 
2014). The presence of HLA genotype-related differences in BMI in children 
without any sings of T1D, as was reported by Yang et al. (Yang et al., 2014) or, 
as shown in the present study, in children with early signs of β-cell autoimmun-
ity speaks against that suggestion. 
The most important result of our study is the demonstration of a significantly 
higher increment in IGFBP-3 before seroconversion to autoantibody positivity 
when compared to the corresponding time interval in autoantibody-negative 
subjects. In the only other relevant study (Beyerlein et al., 2014), the IGF-I and 
IGFBP-3 concentrations were compared at certain time points irrespectively of 
the time of seroconversion, whereas our study looked at the rate of IGF-I and 
IGFBP-3 increments before the time of seroconversion. This approach evaluates 
more directly the role of IGF-I and IGFBP-3 in the process of autoimmunity 
development. 
Our initial hypothesis was that there should be a significant difference in the 
IGF-I/IGFBP-3 molar ratio as one of the proposed markers of bioavailable IGF-
I (Juul et al., 1995). To a lesser degree, we expected to see differences in the 
changes in IGF-I or IGFBP-3 concentrations. In our study only the latter was 
observed. The interpretation of an isolated higher increment of IGFBP-3 
concentrations in autoantibody-positive subjects compared to autoantibody-
negative ones represents a challenge as the serum IGFBP-3 concentration is 
predominantly regulated post-translationally by stabilization through its GH-
dependent binding partners IGF-I and ALS. Thus, at the serum level, IGFBP-3 
is GH-dependent (Baxter and Martin, 1986) but at the transcriptional level, 
independent of GH (Olivecrona et al., 1999). In some diseases, such as T1D and 
obesity, the serum IGF-I concentration is often within the normal range whereas 
the GH level is high reflecting some degree of disintegration of the GH-IGF-I 
axis. (Olivecrona et al., 1999).  We suggest that this type of disintegration of the 
GH-IGF-I axis may exist to some extent also in subjects seroconverting to posi-
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tivity for diabetes-associated autoantibodies. This suggestion is supported by 
the absence of any significant difference in the increment in the IGF-I/IGFBP-3 
molar ratio when autoantibody-positive and negative children were compared in 
the period preceding the seroconversion (see Fig. 7). Such a change in the IGF-
I/IGFBP-3 molar ratio should be expected if the IGFBP-3 increase in the two 
groups is not accompanied by a similar increase in the IGF-I concentration. As 
a matter of fact, a small difference in the mean IGF-I/IGFBP-3 molar ratio was 
actually seen between autoantibody-positive and autoantibody-negative subjects 
when the entire groups were compared at the age of 24 months. However, the 
observations regarding the IGF-I/IGFBP-3 molar ratio should be interpreted 
cautiously in terms of its biological role. Actually it has recently been ques-
tioned whether the IGF-I/IGFBP-3 molar ratio is a reliable marker of free bioac-
tive IGF-I as this has not been validated and proven experimentally (Baxter, 
2014). The molar ratio changes in the same direction as bioavailable IGF-I in 
some, but not in all situations (Frystyk, 2004). 
It is not clear whether IGFBP-3 protects β-cells against autoimmune damage 
or accelerates the death of β-cells. Increasing IGFBP-3 concentrations right 
before seroconversion to autoantibody positivity could be a compensatory reac-
tion that increases the half-life of circulating IGF-I, thus providing β-cell 
protection. An independent role of IGFBP-3 in the development of autoimmune 
β-cell damage cannot be excluded.  The IGF-I-independent apoptotic and 
growth-inhibitory effects of IGFBP-3 have been seen in many different cell 
types (Johnson and Firth, 2014). Furthermore, in several large studies an 
association between IGFBP-3 and the development of type 2 diabetes has been 
observed (Rajpathak et al., 2008; Frystyk et al., 1999; Rajpathak et al., 2012). 
Accordingly, the role of the fast increase in plasma IGFBP-3 concentration right 
before seroconversion will remain a subject for further studies.   
In addition to the lower IGF-I/IGFBP-3 ratio at the age of 24 months in auto-
antibody-positive children compared to autoantibody-negative peers, we also 
have found a similar difference in the IGF-I concentrations at the age of 12 
months. Both findings are different from those reported by Beyerlein et al. 
where serum IGF-I and IGFBP-3 concentrations at 9 and 24 months of age did 
not differ between seropositive and seronegative subjects (Beyerlein et al., 
2014). 
Our study has several limitations. First, the number of children who devel-
oped multiple autoantibodies or T1D was small. It is known that only a minority 
of subjects with one autoantibody will progress to clinical T1D (Knip and 
Siljander, 2008). A second limitation is the modest sensitivity of the IGF-I 
assay with a lower detection limit of 25 μg/L as quite many subjects (13 cases 
and 14 controls) had such results at the time point before seroconversion. The 
interpretation of the results provides also some challenges because of the rela-
tively small number of IGF-I and IGBP-3 samples in the particular subgroups 
based on HLA risk genotypes, and the autoantibody status. This drawback was 
due to the limited availability of plasma samples from the study participants. 
We should also take into consideration possible confounders, such as the dura-
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tion of breastfeeding, which is known to influence the serum IGF-I concentra-
tions (Grunewald et al., 2014). However, the differences in IGF-I and IGFPB-3 
plasma concentrations were seen around 24 months of age when the potential 
effect of breastfeeding should be marginal. 
In conclusion, our study showed that circulating IGF-I and IGFBP-3 may 
play a role in the development of β-cell autoimmunity in young children. These 
results suggest a possible link between the previously reported association be-
tween HLA genotypes and linear growth rate and weight gain in children with 
HLA-conferred susceptibility for T1D. 
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7. CONCLUSIONS 
1. Our study did not confirm the previously reported observation of an associa-
tion between common HLA risk genotypes for T1D and increased birth 
weight. The distribution of birth weight over quartiles in different HLA-risk 
classes or their combinations was not significantly different in any of the 
countries studied as well as in the whole study cohort. However, we found a 
significant association between increased relative birth weight and protective 
alleles DQB1*0602 or DQB1*0603 in cross-combination with the 
DQB1*0302 risk allele. Our observations suggest that the mechanisms be-
hind the association between high birth weight and risk for T1D are hardly 
HLA related.  
 
2. Early postnatal growth in children with HLA genotype conferring very high 
risk for T1D was significantly slower than in those with neutral or protective 
HLA genotypes. Contradictory to our initial hypothesis, the subjects with 
very high risk gained less weight and height during the first 24 months of 
life, and this was more pronounced in the Estonian cohort. We hypothesize 
that the development of T1D requires a higher degree of insulin resistance 
among children with neutral and protective HLA genotypes when compared 
to those with high-risk genotypes. It seems to be more pronounced in Estonia 
with a moderate disease incidence rather than in Finland with the highest 
rate of T1D in the world. 
 
3. Circulating IGF-I and IGFBP-3 may play a role in the development of β-cell 
autoimmunity in young children. Our results suggest a possible link between 
the previously reported association between HLA genotypes conferring risk 
for T1D, early postnatal growth and the IGF-I/IGFBP-3 system. 
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SUMMARY IN ESTONIAN 
Pre- ja postnataalne kasv lastel 1. tüüpi diabeedi riski 
kandvate HLA genotüüpidega 
Üle kogu arenenud maailma kasvab 1. tüüpi diabeedi (T1D) esinemissagedus 
keskmiselt 3–4% aastas (Patterson jt, 2009). T1D etioloogia on multifakto-
riaalne, kus olulist rolli mängivad nii geneetilised kui ka keskkonnafaktorid 
(Knip jt, 2005; Onkamo jt, 1999). Geneetilistest teguritest on tähtsaim HLA 2. 
klassi geenide osakaal, mis moodustavad T1D tekkes kogu geneetilisest riskist 
umbes 50% (Noble jt, 1996; Concannon jt, 2005). HLA riskigenotüübid on 
levinud umbes 20% valgenahalistest inimestest, kuid ainult 5% nendest 
haigestub 1. tüüpi diabeeti (Knip jt., 2005). Isegi geograafiliselt suhteliselt 
väikeses Läänemere piirkonnas erineb T1D haigestumus riigiti kuni 6 
korda (Tuomilehto J jt, 1992; Teeäär jt, 2010; Harjutsalo jt, 2013). Kõik 
need faktid viitavad sellele, et suhteliselt kiire ja püsiva T1D haigestu-
muse tõusu põhjuste taga on eeskätt muutused meie elukeskkonnas, mitte 
geneetilises taustas (Knip jt, 2005; Onkamo jt, 1999).  
Paljud uuringud on näidanud, et enne haiguse avaldumist kasvavad 1. tüüpi 
diabeediga lapsed kiiremini nii pikkuses kui ka kaalus, võrreldes tervete lastega 
(Bloom jt, 1992; Larsson jt, 2008; Ljungkrantz jt, 2008; EURODIAB Substudy 2 
Study Group, 2002; Hyppönen jt, 2000; Knerr jt, 2005). Nende tulemuste valguses 
püstitati nn. aktseleratsiooni või ülekoormuse hüpotees (Wilkin, 2001). Selle 
hüpoteesi kohaselt viib pidev toidu üleküllus, rasvumine ja kiirenenud kasv juba 
varases lapsepõlves insuliini produktsiooni vajaduse tõusuni, mille tulemusel 
kõhunäärme β-rakud on sunnitud intensiivsemalt töötama, mis  muudab nad aga 
igasuguse stressi suhtes vastuvõtlikumaks. Viimane omakorda kiirendab apoptoosi 
(programmeeritud rakkude surm) ja rakkude destruktsiooni erinevate faktorite 
toimel (Wilkin, 2001). Olulist rolli selle hüpoteesi kohaselt mängib insuliini 
resistentsus, mille väljakujunemist soodustab liigne kaalutõus. Insuliini resistentsus 
stimuleerib β-rakkude metaboolset aktiivsust, suurendab nende haavatavust ja 
antigeenseid omadusi (Wilkin, 2001). Viimane soodustab omakorda 
autoimmuunset kõhunäärme Langerhansi saarekeste põletikku (Dahlquist, 2006; 
Gale, 2005) ja β-rakkude kadu (Wilkin, 2009). Suurema sünnikaalu ja T1D 
haigestumise riski vaheline positiivne korrelatsioon osutab sellele, et kiirenenud 
kasv koos teiste keskkonnafaktoritega võivad mängida olulist rolli T1D 
väljakujunemises juba intrauteriinselt (Cardwell jt, 2010; Harder jt, 2009).  
1. tüüpi diabeedi eelsoodumust põhjustavate geneetiliste faktorite roll 
kiirenenud pre- ja postnataalses kasvus ei ole selge. Publitseeritud on rida 
uuringuid, mis on andnud vasturääkivaid tulemusi. On leitud, et teatud HLA 
genotüübid mõjutavad kasvu positiivselt, teised negatiivselt (Carlsson jt, 2012; 
Larsson jt, 2005; Larsson jt, 2008; Stene jt, 2001; Järvinen jt, 2008; Yang jt, 
2014). Osa uuringuid on näidanud, et ka keskkonnategurid võivad mõjutada 
HLA genotüübi ja kasvamise vahelist seost (Taylor jt, 2006; Hummel jt, 2007; 
Larsson jt, 2007). Kuna ka keskkonnafaktorid mängivad olulist rolli T1D 
87 
 
esinemissageduse tõusus (Knip jt, 2005; Onkamo jt, 1999), võib oletada, et 
HLA genotüüpide mõju kasvule võiks olla rohkem väljendunud kõrge T1D 
esinemissagedusega riikides. Sellistes riikides peaks diabetogeense keskkonna 
surve kasvule ning HLA genotüübi ja kasvu vahelisele seosele olema suurem. 
Käesoleva ajani läbiviidud uuringud on piirdunud enamasti ühe riigiga 
(Järvinen jt, 2008; Larsson jt, 2005; Stene jt, 2006) või väga sarnase T1D 
esinemissagedusega riikidega (Yang jt, 2014; Sterner jt, 2011). 
Kuna kasvuhormooni ja insuliini sarnase kasvufaktori I (IGF-I) telg on 
lapseeas kõige olulisem kasvu reguleeriv süsteem, siis diabeedi avaldumisele 
eelnev kiirenenud kasv võib osutada sellele, et IGF-I võib mängida olulist rolli 
ka diabeedi tekkes. Sellele viitavad uuringud, mis on näidanud IGF-I (Agudo jt, 
2008; Anguela jt, 2013; Castrillo jt, 2000; George jt, 2002) ja seda peptiidi 
siduva peamise valgu (binding protein) (IGFBP-3) (Jones ja Clemmons, 1995; 
Butler jt, 1996; Chan jt, 2005; Kim jt, 2007) rolli T1D arengus. Mitmed loom-
mudelid on näidanud, et IGF-I suurendab eksisteerivate β-rakkude replikat-
siooni ja proliferatsiooni pärast kahjustust (Agudo jt, 2008), kaitseb β-rakke 
apoptoosi (Castrillo jt, 2000) ja Langerhansi saarekesi lümfotsütaarse infiltrat-
siooni eest (George jt, 2002) ning pidurdab autoimmuunse diabeedi progres-
siooni (Anguela jt, 2013). IGFBP-3 omab rida IGF-I sõltumatuid funktsioone 
(Kim, 2014; Johnson ja Firth, 2014), mille roll diabeedi patogeneesis on jäänud 
ebaselgeks. Mõned uuringud on näidanud positiivset seost seerumi IGFBP-3 
taseme ja 2. tüüpi diabeedi vahel  (Frystyk jt, 1999; Rajpathak jt, 2012). Tsirku-
leeriva IGF-I ja IGFBP-3 rolli β-rakkude vastase autoimmuunsuse välja-
kujunemises on uuritud väga vähe, nagu ka IGF-I ja IGFBP-3 süsteemi ning 
HLA genotüübi  kombineeritud mõju varajasele postnataasele kasvule.  
 
 
Uurimuse eesmärgid 
1. Uurida T1D riski kandvate HLA genotüüpide mõju  sünnikaalule  ja nende 
omavahelisi seoseid kolmes väga erineva T1D  esinemissagedusega riigis. 
2. Uurida T1D riski kandvate HLA genotüüpide mõju varajase postnataalse 
kasvu ja T1D riski vahelisele seosele  kahes väga erineva T1D  esinemis-
sagedusega riigis. 
3. Uurida veres tsirkuleeriva IGF-I ja IGFBP-3 rolli β-rakkude vastase auto-
immuunsuse väljakujunemises ning nende võimalikku mõju T1D riski kandvate 
HLA genotüüpide ja varajase postnataalse kasvu vahelisele seosele.  
 
 
Patsiendid ja meetodid 
Käesolev töö toimus Euroopa Liidu 7. raamprojekti poolt finantseeritud uuringu 
DIABIMMUNE raames. Selle käigus genotüpiseeriti T1D riski kandvate HLA 
haplotüüpide suhtes ligi 12000 last Eestis, Soomes ja Venemaal Karjalas. 
Genotüpiseerimine toimus PCR-baasil, kasutades lantaniidiga markeeritud 
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hübridisatsiooni ja aeglahutatud fluoromeetria meetodit (Mikk jt, 2014). Esiteks  
toimus analüüs HLA DQB1*02, DQB1*0301, DQB1*0302 ja DQB1*0602/3 
alleelide esinemise suhtes (Kiviniemi jt, 2007). Kui see analüüs kinnitas, et 
tegemist on riski, neutraalse või protektiivse genotüübiga, siis edasist täpsemat 
genotüpiseerimist ei tehtud. Teistel juhtudel teostati rida täiendavaid analüüse, 
et välja selgitada lõplik riski suurus. 
Esimeses uuringus kasutati esialgu 8369 vastsündinu andmeid. Diabeediga 
emade, enne 35 gestatsiooninädalat või mitmikrasedusest sündinud laste and-
med eemaldati analüüsist. Seega jäi uuritavaid lapsi esimesse uuringusse 7931. 
Igale lapsele arvutati suhteline sünnikaal, mis väljendati  standardhälve punk-
tina (SDS), mille arvutamiseks kasutati vastava riigi soole ja gestatsiooni-
vanusele vastavaid sünnikaalu aritmeetilise keskmise ja standardhälve (SD) 
väärtusi.  Lähtudes HLA genotüüpidest, jaotati lapsed nelja rühma vastavalt 
T1D riskile: väga kõrge, kõrge ja mõõduka riskiga ning neutraalse/protektiivse 
HLA genotüübiga rühmadeks. Sünnikaalude jaotuvus kvartiilide vahel igas 
riskirühmas analüüsiti rühmasiseselt, rühmade vaheliselt kogu uuritavas 
kohordis ja ka riigiti eraldi.  
Teises uuringus osales 496 last Eestist ja Soomest, kellel DIABIMMUNE 
uuringu raames oli vastsündinuperioodis avastatud T1D suurenenud riski kand-
vad HLA genotüübid ja 191 Eesti last neutraalse või protektiivse genotüübiga. 
DIABIMMUNE uuringus jälgiti T1D suurenenud riskiga laste kasvu 24 kuu 
vanuseni, neutraalse või protektiivse HLA genotüüpidega laste kasvu andmed 
saadi perearstide käest. Analoogselt esimese uuringuga, lähtudes HLA geno-
tüüpidest, jaotati lapsed nelja riskirühma. Igale lapsele arvutati suhteline pik-
kuse SDS ja kaalu SDS vanuses 3, 6, 12, 18, ja 24 kuud, kasutades selleks soole 
ja vanusele vastavaid WHO kasvukõveraid (WHO Multicentre Growth 
Reference Study Group, 2006). Kuna Kolmogorov-Smirnovi testi tulemusena ei 
erinenud andmete jaotuvus erinevates rühmades normaalsest jaotuvusest, 
kasutati rühmade kaalude SDS ja pikkuste SDS võrdlemiseks  ANOVA testi 
koos post hoc Tukey HSD analüüsiga. 
Kolmandas uuringus osales 563 DIABIMMUNE uuringu last Eestist ja 
Soomest, kellel esinesid T1D riski kandvad HLA genotüübid. Vanuses 3, 6, 12, 
18, 24 ja 36 kuud määrati neil vereseerumis autoantikehad IAA, GAD65, IA-2, 
ZnT8 ja ICA, kasutades selleks vastavaid spetsiifilisi teste ja piirväärtusi (Knip 
jt, 2010). Kui üks nendest autoantikehadest osutus positiivseks, nimetati seda 
serokonversiooniks. Kõigil 40 lapsel, kellel tekkis serokonversioon, määrati 
plasma IGF-I ja IGFBP-3 kontsentratsioon. IGF-I ja IGFBP-3 määrati ka 80 
lapse kontrollil, kes sobitati vanuse, soo, päritoluriigi ja HLA genotüüpi järgi 
sama kohordi laste seast, kuid kellel serokonversooni ei esinenud. IGF-I ja 
IGFBP-3 määrati tahkefaasilise ensüümiga markeeritud kemiluminestsents-
immunomeetrilise testiga kasutades IMMULITE 2000 analüsaatorit. Lisaks 
arvutati IGF-I ja IGFBP-3 molaarne suhe (IGF-I/IGFBP-3). Selles uuringus 
jagati lapsed, kellel kõigil oli suurenenud risk T1D tekkeks, HLA genotüüpide 
alusel kolme riskirühma: kõrge, mõõduka ja väikese (kuid suurenenud) riskiga 
haigestuda T1D. IGF-I ja IGFBP-3 taset võrreldi autoantikehade suhtes 
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negatiivsete ja positiivsete laste vahel ning erinevate HLA riskirühmadesse 
kuuluvate laste vahel. Andmete jaotuvust kontrolliti Kolmogorov-Smirnovi 
testiga. Autoantikehade suhtes negatiivsete ja positiivsete laste võrdluseks 
kasutati paaritut kahepoolset Student t-testi, mitte-normaalse andmete jaotuvuse 
korral Mann-Whitney U-testi. IGF-I ja IGFBP-3 taset erinevates riskirühmades 
võrreldi ANOVA testi abil koos post hoc Tukey HSD analüüsiga, mitte-
normaalse jaotuvusega andmete puhul Kruskal-Wallis testi abil post hoc 
Bonferroni (Dunn) t-testiga. Samuti määrati IGF-I, IGFBP-3 ja IGF-I/IGFBP-3 
juurdekasv ajamomentidel enne ja pärast serokonversiooni, kontroll-lastel 
analoogsetel ajamomentidel. Rühmadevaheline võrdlus tehti paaris t-testiga. 
 
 
Tulemused 
Esimeses uuringus otsest seost erinevate T1D riski kandvate HLA genotüüpide 
(HLA DR3-DQ2/DR4-DQ8, DR3-DQ2/X ja DR4-DQ8/X) ja sünnikaalu vahel 
kogu uuritavas kohordis, samuti ka eraldi vaadeldud riikides, ei leitud. Samas, 
protektiivsed alleelid HLA DQB*0602 ja 603 kombinatsioonis riskialleeliga 
HLA DQB1*0302 assotsieerusid suure sünnikaaluga: esimeses kvartiilis oli 
lapsi 18% versus 29% neljandas  kvartiilis (P=0.003; OR=0.52 (CI=0.36–0.75). 
Teises uuringus leidsime, et T1D suurimat riski kandva HLA genotüübiga 
(DR3-DQ2/DR4-DQ8) laste keskmise pikkuse SDS 24 kuu vanuses on oluliselt 
väiksem, võrreldes lastega, kel oli neutraalne/protektiivne genotüüp (p<0.05). 
Sama kehtis ka kaalu SDS suhtes vanuses 12, 18 ja 24 kuud (p<0.05). Kahe riigi 
kohordi eraldi analüüs näitas, et pikkuse SDS ja kaalu SDS osas säilisid 
mõlemas riigis sarnased trendid nagu kogu kohordis, kuid statistiliselt oluline 
erinevus oli vaid kaalu SDS osas ja ainult Eestis (p<0.05). 
Kolmandas uuringus olid plasma IGF-I kontsentratsioon 12 kuu vanuses ja 
IGF-I/IGFBP-3 24 kuu vanuses oluliselt madalamad lastel, kellel olid tekkinud 
autoantikehad, võrreldes nendega, kellel neid polnud (p<0.05). Tsirkuleeriva 
IGFBP-3 juurdekasv enne serokonversiooni oli oluliselt suurem, võrreldes 
kontroll-lastega (0.43 mg/l; 95% CI 0.29–0.56 versus 0.22 mg/l; 95% CI 0.10– 
0.34 mg/l; p<0.01). Võrreldes väiksesse riskirühma kuuluvate lastega, oli kõrge 
T1D riski genotüübiga lastel plasma IGF-I ja IGFBP-3 tase 24 kuu vanuses 
oluliselt madalam (vastavalt p<0.05 ja p<0.01).  
 
 
Järeldused 
Meie uuring ei leidnud seost T1D riski kandvate HLA genotüüpide ja sünni-
kaalu vahel. Seos suurema sünnikaaluga oli ainult spetsiifilisel genotüübil, kus 
on kombineeritud protektiivsed alleelid DQB1*0602 või DQB1*0603 riski-
alleeliga DQB1*0302.  
Lapsed, kes on suurima geneetilise riskiga haigestuda T1D (HLA genotüüp 
DR3-DQ2/DR4-DQ8), kasvavad esimesel kahel eluaastal nii pikkuses kui ka 
kaalus aeglasemalt, võrreldes lastega, kel suurenenud risk puudub (neut-
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raalse/protektiivse HLA genotüübiga). See seos on enam väljendunud Eestis, 
kus T1D esinemissagedus on oluliselt madalam kui Soomes. 
Tsirkuleeriv IGF-I ja IGFBP-3 võivad osaleda β-rakkude vastase auto-
immuunsuse väljakujunemises. Uuringu tulemused osutavad võimalikule seo-
sele T1D riski kandvate HLA genotüüpide poolt modifitseeritud postnataalse 
kasvu ning  IGF-I ja IGFBP-3 süsteemi vahel. 
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